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The development of recombinant proteins for therapeutic applications has 
revolutionized the pharmaceutical industry. In particular, monoclonal antibodies are the 
safest class of all therapeutic molecules and account for the majority of recombinant 
proteins currently undergoing clinical trials. A variety of technologies exist to engineer 
antibodies with a desired binding specificity and affinity, both of which are a prerequisite 
for therapeutic applications. This dissertation describes the implementation of a novel 
combinatorial library screening technology for the discovery and engineering of 
antibodies with unique binding properties. Combinatorial library screening technologies 
are used for the in vitro isolation of antibodies from large ensembles of proteins 
(libraries) typically produced by microorganisms using molecular biology techniques. 
Our lab has developed a powerful antibody discovery technology that relies on E. coli 
display by anchored periplasmic expression, otherwise known as APEx.  
 vii 
First, I compared the effects of using combinatorial libraries comprising either 
smaller, monovalent single-chain antibody fragments (scFv), or the much larger, 
bifunctional full-length IgG antibodies. These technologies were used to isolate a small 
panel of antigen specific antibodies from the same library of antibody variable domains 
amplified from a mouse immunized with the Protective Antigen (PA) component from 
Bacillus anthracis, the causative agent of anthrax. Overall, IgG display resulted in the 
isolation of a broader panel of variable domain sequences. Most of these variable 
domains exhibited substantially reduced affinity when expressed as scFvs, which is 
consistent with the finding that none of these could be isolated from the equivalent scFv 
library. These results indicate that the antibody format used during in vitro selection 
affects which antibody variable domains will be discovered.  
Second, I developed several modifications of the APEx methodology to allow for 
more efficient recovery of antibodies with desired properties. Specifically, the system 
was reengineered to simultaneously account for antibody binding and expression levels in 
order to isolate the highest affinity antibodies with favorable expression characteristics.  
Third, the new approach, coupled with optimized fluorescence activated cell 
sorting (FACS) settings, was used to increase the affinity of an antibody by 35-fold 
resulting in a KD of 100 pM. It was demonstrated that genetic transfer of this high affinity 
antibody specific for the V antigen of Yersinia pestis, the etiologic agent of the plague, 
conferred increased protection against intranasal challenge with a 363 LD50 of Y. pestis in 
mice. 
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Engineering Therapeutic Antibodies 
 
INTRODUCTION 
Antibodies are produced by the immune system of vertebrates in a defensive 
response to invasion of foreign agents such as microorganisms and viruses. They have the 
ability to recognize a diverse array of molecules, referred to as antigens, including 
proteins, peptides, small molecules, lipids, carbohydrates, and DNA, with an exquisite 
degree of specificity and affinity. For these reasons, antibodies have been successfully 
exploited in therapeutic, diagnostic, and analytical applications since the late 19th century 
(56). 
Antibody therapy was revolutionized by the development of the hybridoma cell 
line in 1975 (86). It circumvented the major limitations of the earlier polyclonal antibody 
therapies and provided an efficient means to generate monoclonal antibodies. 
Monoclonal antibodies are produced by individual B cells and are specific for one 
particular site on an antigen known as an epitope. The interaction between an antibody 
and antigen in vivo can result in a therapeutic benefit. Although the hybridoma 
technology is still used today, the antibodies they produce are of murine origin and are 
frequently immunogenic when administered to humans. Fortunately, recent advances in 
molecular biology have enabled the development of numerous in vitro technologies for 
the discovery and engineering of human antibodies (72). These technologies have been 
created in an attempt to mimic the in vivo generation and selection of antibody diversity 
by the immune system. They tend to expedite the discovery process, can be parallelized, 
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and allow the researcher to finely tune antibody properties (72). They also circumvent the 
biological constraints of antibodies generated in vivo which allows the generation of 
antibodies with higher affinities and toward toxic or non-immunogenic molecules (42, 
45). Regardless of the technology used, the overall goal of antibody discovery and 
engineering is to isolate antigen specific monoclonal antibodies.  
Monoclonal antibodies are frequently associated with healthcare since they are 
being used to treat a wide array of diseases (23). There are currently 18 FDA approved 
antibodies for use with transplantation, oncology, autoimmune, cardiovascular, and 
infectious diseases, and several other candidates are being developed for the treatment of 
a variety of indications (Table 1.1) (58, 99, 129, 154). Antibody-based therapeutics 
generated $20.6 billion in worldwide sales in 2006, which exceeded prior forecasts (99). 
This number is even more astonishing since the first FDA approved monoclonal antibody 
was MabTheraTM (Rituximab) in 1997. The rapid growth of the therapeutic antibody 
market has resulted in over 100 companies generating antibody-based drugs toward 
hundreds of targets. With more than 150 monoclonal antibodies currently undergoing 
clinical evaluation, they account for the majority of recombinant protein drugs (24, 99, 
129). This growth is predicted to continue because antibodies have established a track 
record for both safety and efficacy evident by their FDA approval rate being two to three 
times higher than other drug classes (129). Finally, discoveries in basic pathogenesis are 







Table 1.1.  FDA Approved monoclonal antibodies 
Brand name 











    
Ortho Biotech  Products Mouse IgG2a 0.83 Immunological 1986 
ReoPro 




Biogen Idec Chimeric IgG1 8 Oncological 1997 
Zenapax 
(daclizumab) Hoffman-LaRoche Humanized IgG1 0.3 Immunological 1997 
Simulect 




Abbott Laboratories Humanized IgG1 0.96 Anti-infective 1998 
Remicade 
(infliximab) 
Johnson & Johnson, 




LaRoche Humanized IgG1 5 Oncological 1998 
Mylotarg 
(gemtuzumab ozogamicin ) Wyeth 
Humanized IgG4, 




Schering Humanized IgG1 10-32 Oncological 2001 
Zevalin 
(ibritumomab tiuxetan) Biogen Idec 
Mouse IgG1,  
90Y-labeled 14-18 Oncological 2002 
Humira 
























Elan Humanized IgG4 0.3 Immunological 2004 
Vectibix 
(panitumumab) Amgen Human IgG2  Oncological 2006 
   
aInformation obtained from published literature (24, 130, 164). 




There are several classes of antibodies known as isotypes, of which the 
immunoglobulin G (IgG) is the most abundant in human serum. IgG proteins are 
heterodimers of four covalently linked polypeptides known as the heavy and light chains, 
which come together and form the classic “Y”-shaped antibody structure. The stem of the 
“Y” is known as the crystallization or constant fragment (Fc) and the two identical arms 
are known as the antigen binding fragments (Fab) (Figure 1.1). 
 
 
Figure 1.1.  Immunoglobulin G (IgG) antibody structure. 




The Fc is constant for each antibody isotype and is responsible for interacting 
with the cells of the immune system to initiate antibody mediated effector functions. The 
Fab, as its name suggests, is responsible for antigen binding, and they can be obtained by 
proteolytic cleavage from the Fc either as a monomeric species or as a pair (F(ab’)2) 
without altering their original binding properties. Binding occurs through the unique 
variable domains that are located on the N-terminus of the heavy and light chains, VH and 
VL, respectively. Each variable domain is comprised of three hypervariable loops, 
otherwise known as complementarity determining regions (CDR), which are supported 
by four structural framework regions. The vast sequence diversity contained within these 
variable regions enables antibodies to bind to a diverse array of antigens with both high 
specificity and affinity.  
 
RECOMBINANT ANTIBODIES 
In the late 1980’s, molecular biology techniques enabled the facile cloning and 
expression of recombinant antibodies in bacteria, primarily in the Gram-negative 
bacterium Escherichia coli (146). E. coli is an ideal host for the expression of 
recombinant proteins, including antibodies, because it is easy to genetically manipulate, 
inexpensive to work with, and requires short periods for growth. However, in early 
studies it was not possible to produce full-length antibodies in E. coli in soluble form due 
to their size and complexity, thus recombinant antibody fragments are frequently used 
(106). Recombinant antibody fragments are generated by dissecting full-length antibodies 
into “minimalistic” binding domains through molecular biology techniques (Figure 1.2). 
These antibody fragments express well in E. coli and typically maintain the binding 
capabilities of their full-length counterparts (70, 106). Although single VL and VH 
domains can retain binding specificity, they are typically unstable and have lower 
affinities than their IgG counterparts (70). Therefore, the most widely used form of a 
recombinant antibody fragment is the single chain variable fragment (scFv), which is 
generated by fusing the VL and VH domains with a flexible polypeptide linker (13). A 
variation of the scFv is the single chain antibody (scAb), which is a fusion between a 
scFv and the light chain kappa constant domain (CΚ) (110). Additional forms of 




Figure 1.2.  Recombinant antibody formats. 




ANTIBODY SPECIFICITY AND AFFINITY 
The two most important features of any form of an antibody, whether it is an IgG 
or a scFv, are its specificity and affinity for its antigen. This is determined by the amino 
acid sequences of the light and heavy chain variable domains and particularly the CDR 
sequences. Specificity is the ability of an antibody to recognize and interact with one 
particular antigen over another and form an immune complex. The exact region of the 
antigen that the antibody interacts with is its epitope. Most antigens have multiple 
epitopes that different antibodies are specific for and can bind to simultaneously, which 
helps facilitate antigen clearance by the immune system. The immune complexes can be 
in solution, or they can be insoluble if either the antibody or antigen is immobilized on a 
surface. 
Affinity is the standard performance criterion of an antibody and is defined by an 
equilibrium binding constant (KD) as follows:  
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[Antibody] + [Antigen]                 [Antibody:Antibody] 
The KD is a ratio of the dissociation (koff) and association (kon) rate constants of the 
antigen-antibody complex and results in units of molarity. A higher affinity antibody has 
a higher propensity to remain in complex with its antigen and results in a lower KD. 
Various methods have been created to measure either KD or the individual rate constants 
(104). Of these, surface Plasmon resonance (SPR) has emerged as the industry standard 
since it is capable of real-time measurements over a wide range of affinities (104). 
Surface Plasmon resonance (SPR) is an optical technology designed to measure 
the kinetic interaction between different molecules. It is a label free technology so it 
avoids the complexity that can arise from labeling the molecules, which can also 
compromise the integrity of their interaction with the other molecule (133). One 
koff (s-1)
kon (M-1s-1)
particular SPR instrument that is commonly used is the BiacoreTM. It is a microfluidic 
device in which one molecule (ligand) is covalently immobilized to a derivatized dextran 
matrix on the surface of sensor chip using primary amine or other standard chemistry. 
The other molecule (analyte) is injected by a robotic system and flowed across the 
surface for a set amount of time (Figure 1.3). The change in mass on the surface of the 
chip as a result of an interaction between the two molecules is monitored by a change in 
the refractive index of light that is reflected by the surface. This is used to generate in 
real-time an interaction profile called a sensogram. The sensograms generated under 
different experimental conditions are analyzed using supplied mathematical software to 
determine either the association (kon) and dissociation (koff) rate constants or the overall 
equilibrium constant (KD). 
 
 
Figure 1.3.  Surface Plasmon resonance. 
The image is reproduced with permission from Journal of Molecular Recognition (84). 
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ANTIBODY EFFECTOR FUNCTION 
Antibodies interact with the innate immune system through their Fc region by 
binding Fc receptors present on the surface of certain types of leukocytes. The interaction 
is dependent upon the antibody isotype and often results in effector functions performed 
by the cells (Figure 1.4). The effector functions eliminate immune complexes by 
opsonization, antibody dependent cell-mediated cytotoxicity (ADCC), or complement 
dependent cytotoxicity (CDC). The method of elimination is dependent upon the type of 
immune complex formed. Additional effector functions involving both cells within and 
outside of the immune system are antigen independent and are required to maintain 
antibody serum concentration homeostasis amongst other things (56).  
Pathogens, such as a bacterium, have an array of immunogenic surface antigens 
that can be simultaneously bound by multiple antibodies. The close proximity of these 
antibody Fc regions allows them to interact simultaneously with multiple Fc receptors on 
the surface of phagocytes, such as macrophages and neutrophils. This crosslinks the 
receptors and triggers a signal transduction cascade that enhances phagocytosis and leads 
to the destruction of the pathogen inside the cell. This process is referred to as 
opsonization. 
Opsonization is not always effective at eliminating immune complexes. Some 
virus infected, bacterially infected, and cancerous cells that are recognized by antibodies 
are too large and are destroyed through ADCC. The antibodies interact with Fc receptors 
on the surface of several cell types including natural killer (NK) cells, macrophages, 
eosinophils, and neutrophils. These cells destroy the targeted cell through multiple 
mechanisms leading to cell lysis or apoptosis. 
Antibodies can eliminate pathogens and toxins via the complement system, a 
biochemical defense cascade associated with innate and humoral immunity. The close 
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proximity of multiple antibody Fc regions on the surface of a pathogen initiates the 
enzymatic cascade of the classical complement pathway, which ultimately results in 
formation of the membrane attack complex (MAC). The MAC perforates the bacterial 
cell membrane resulting in loss of osmotic stability followed by cell lysis. An important 
byproduct of activating the classical pathway is the activation of complement protein 
C3b, which binds non-specifically to immune complexes near the site of complement 
activation. C3b bound to the surface of a pathogen can initiate the alternative complement 
pathway, another biochemical cascade that results in MAC formation then cell lysis. The 
bound C3b can also interact with a receptor on the surface of erythrocytes which deliver 
the immune complexes to the liver and spleen. C3b can also act as an opsonin, initiating 
phagocytosis by interacting with complement receptors on the surface of immune cells.  
IgG also interacts with the neonatal Fc receptors (FcRn) expressed on the surface 
of a variety of cell types including vascular, pulmonary, and intestinal epithelial cells, as 
well as antigen presenting cells (136). The expression patterns vary between cells of 
different species and can be age dependent. FcRn was first discovered as the means by 
which IgG is transferred from a human mother to her fetus, which is a form of passive 
immunity. It is now known to be involved in a variety of other biological functions. For 
example, the prolonged half-life and increased serum concentration of IgG compared to 
other isotypes are attributed to interactions with FcRn. This ensures that there is a 
sustained amount of IgG in circulation to efficiently initiate an immune response. In 
addition, FcRn is responsible for the transcytosis of IgG across intestinal epithelial cells 
where it can interact with mucosal pathogens and activate an immune response before the 
pathogen enters circulation. 
 
Figure 1.4.  Effector functions. 
The image is reproduced with permission from Nature (100). 
 
ANTIBODY GENERATION IN VIVO 
The immune system contains primary and secondary defense levels that vary in 
their specificity and adaptability. The innate immune system is the broadly specific and 
non-adapting component that provides the first level of defense. All organisms of a given 
species contain the same cellular and molecular components of the innate immune 
system, which recognize common properties of foreign agents, also referred to as non-
self. The adaptive immune system is the highly specific and adaptable component that 
provides the second level of defense. It recognizes and responds to individual foreign 
agents in order to provide additional specific protection as needed through a process that 
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is dependent upon some cellular components of the innate immune system. The adaptive 
immune system not only varies between organisms, but within the same organisms over 
time since it reacts to the environment in a specific manner. 
The adaptive immune system is regulated by the cooperation between antigen 
presenting cells and B and T lymphocytes, and is responsible for distinguishing between 
self and non-self agents, coordinating the immune response, and providing memory of 
previous responses to efficiently react to reoccurring exposures. The antigen presenting 
cells bridge the innate and adaptive immunity. These specialized cells take up antigen 
from pathogens and display markers to the T cells so they can determine what is self and 
non-self and regulate B cell production of antibodies for the humoral immune response. 
Lymphocytes provide the attributes of specificity and diversity to the adaptive immune 
system, which changes with time. 
 
Humoral Immune Response 
B cells circulate around the body in an inactivated state while the membrane 
bound antibodies on their surface perform surveillance of the body for the immune 
system. The antigen specificity of these antibodies is determined by the amino acid 
sequence of each of their variable domains, which are derived from the same limited pool 
of variable domain gene segments (Figure 1.5). The heavy chain variable domain (VH) is 
divided into multiple V, D, and J gene segments while the light chain variable domain 
(VL) is divided into multiple V and J gene segments. These gene segments are 
individually assembled in a combinatorial fashion to generate an enormous amount of 
sequence diversity. This combinatorial assembly is coupled with additional mechanisms 
that further expand the sequence diversity, which is estimated to be over 1010 for humans 
(56). This process occurs in the bone marrow and is where the antibodies on the surface 
of each immature B cell are pre-screened in a highly regulated process to minimize 
recognition of self antigens and the onset of autoimmunity. B cells that make it through 
this process are classified as naïve B cells and circulate throughout the body. 
 
 
Figure 1.5.  Combinatorial assembly of antibody germline gene segments. 
Antibody variable domain diversity is obtained by random combinatorial assembly of V, 
D, and J gene segments, junctional diversity through the random addition and deletion of 
nucleotides at the joints between the gene segments, and somatic hypermutation mutation 
of the entire variable domain, which becomes most prevalent during the secondary 
immune response. Only one heavy chain constant domain is shown. The image is 
reproduced with permission from Nature (95). 
The primary immune response begins when a naïve B cell is specifically activated 
through a process involving the interaction between the membrane bound antibodies on 
its surface and their antigen. The exact mechanism of this process varies depending upon 
the antigen encountered, but it is often thymus-dependent and relies upon the presence of 
a subset of T cells called T helper cells (TH). Activated B cells migrate toward germinal 
centers, which are microenvironments located in the lymph nodes and spleen that 
facilitate B cell proliferation, selection, and differentiation (Figure 1.6). Their antibody 
variable domain genes are mutated during proliferation through a process called somatic 
hypermutation, which leads to affinity maturation. This process primarily targets the 
CDR regions of the VH and VL domains and occurs at approximately one mutation per 
division, a rate one million-fold faster than normal (56). Mutations resulting in antibodies 
with higher affinities (lower KD) toward the foreign agent enable those B cells to survive 
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the antigen selection process by out competing for the limited supply of antigen located 
in the germinal center, while the other B cells undergo apoptosis and die. Surviving B 
cells must receive a stimulatory signal from TH cells before undergoing differentiation 
into antibody secreting plasma cells and memory B cells. These cell types generate 
antibodies specific for the current invading foreign agent and dominate the total B cell 




Figure 1.6.  B cell proliferation, selection, and differentiation. 
The image is reproduced with permission from Nature (85). 
The plasma cells are responsible for producing soluble antibodies that assist in the 
immediate elimination of the foreign agent from the body. The maximum antibody 
concentration of these specific antibodies in the serum, referred to as a serum titer, occurs 
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one to two weeks following initial agent exposure and is dependent upon the route of 
exposure (56). Once secreted, the antibodies can bind to the agent and interact with cells 
of the innate immune system and with the complement system through their Fc region. 
This leads to various effector functions that facilitate agent removal. Most plasma cells 
do not have a long life expectancy and undergo apoptosis once the antigen has been 
eliminated, which typically requires days to weeks (56). However, some plasma cells 
migrate to the bone marrow where they persist for extended periods of time and continue 
to secrete antibodies (56, 144). 
A memory B cell can last the lifetime of the individual and initiate a secondary 
immune response. The secondary immune response occurs following repeat exposure to 
the same foreign agent leading to the activation of memory B cells. As with naïve B cells, 
memory B cells are activated when antibodies on their surface interact with their specific 
antigen and this is more efficient in the presence of TH cells, especially memory TH cells. 
Activation of the memory B cells again leads to clonal expansion, but the response is 
faster, more prolonged, and results in higher antibody titers because the memory B cells 
are easier to activate and are present in greater quantities compared to naïve B cells (56). 
Whether or not these memory B cells undergoes subsequent somatic hypermutation in 
germinal centers to further increases the antibody affinity toward its antigen is a 
controversial subject (111, 124, 153). The entire process of the immune response results 
in a heterogeneous population of antibodies circulating in the blood. These antibodies are 
capable of recognizing, with varying affinities, a variety of epitopes on the foreign agent 
and help coordinate its removal from the body. 
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Polyclonal Serum and Passive Immunity 
Antibodies produced as part of the humoral immune response can be transferred 
from the immune individual to a non-immune individual and provide immunity. This 
process is called “passive immunity” and was first demonstrated in the late 19th century 
by Emil von Behring and Kitasato Shibasaburo (160). In their studies, they took mice that 
were immune to diphtheria and extracted the serum fraction of their blood by removing 
all the cellular components, allowing the remaining plasma to clot, then isolating the fluid 
fraction. They transferred this serum to guinea-pigs infected with diphtheria which cured 
them. This therapeutic approach was referred to as “serum therapy” since it was not 
known that antibodies were responsible for eliminating the infection.  
A few years later, Behring teamed up with Paul Ehrlich to produce serum therapy 
that could be used on humans (160). Ehrlich previously demonstrated the concept of 
active immunity by building up an animal’s tolerance to a toxin by gradually increasing 
exposure to it. The process is referred to as immunization. They used this approach to 
immunize dairy cattle and mass produced serum that was successfully used on thousands 
of humans suffering from diphtheria. Serum therapy has been used to cure other 
infectious diseases and is still used today for certain indications (12, 25, 117). 
It was not long before researchers demonstrated that serum from immune donors 
could neutralize and precipitate toxins as well as agglutinate bacteria (56). Until the 
1930’s, it was thought that different substances were responsible for these different 
activities. However, Arne Tiselius and Elvin Kabat determined the gamma-globulin 
fraction of serum was responsible for all these activities and called them 
immunoglobulins, also known as antibodies. 
Serum therapy was a revolutionary breakthrough that saved thousands of lives 
over the course of history, and for its discovery, Behring was awarded the Nobel prize in 
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1901 (25, 56). Unfortunately, mild to severe complications were often associated with 
serum therapy, which involved large serum dosages containing various animal proteins, 
including antibodies, which are immunologically incompatible in humans (56). The 
humoral immune response generates antibodies specific for the animal proteins resulting 
in a high quantity of immune complexes. This can lead to symptoms that mimic an 
allergic reaction and is referred to as serum sickness (56).  
Advances in purification techniques have enabled the production of polyclonal 
antibody preparations from serum with reduced toxicity (117). However, the polyclonal 
populations of antibodies isolated from different serum preparations results in 
inconsistent and non-specific biological activities and thus are rarely used for therapy 
today. These approaches are mainly used to produce research grade polyclonal antibodies 
for analytical and diagnostic applications (33). They are especially useful reagents when 
a high level of sensitivity is required since they consist of a heterogeneous population of 
antibodies that can bind a variety of epitopes on the same antigens simultaneously. The 
need for the reliable production of identical antibodies with known properties, especially 
for therapeutic applications, resulted in the development of technologies to produce 
monoclonal antibodies. 
 
The Hybridoma Technology 
In 1948, antibodies found in serum were shown to be produced from plasma B 
cells (145). Unfortunately, typical B cells are difficult to cultivate and are not suitable for 
antibody production in vitro. However, cancerous B cells known as myelomas are readily 
cultivated in vitro and can lose their ability to produce antibodies. In 1975, Milstein and 
Kohler created a stable cell line capable of continuous production of a single monoclonal 
antibody in vitro by fusing an antibody producing B cell with a myeloma cell (86), 
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referred to as a hybridoma. The development of the hybridoma technology marks the 
beginning of antibody engineering. 
In order to generate a hybridoma that produces a monoclonal antibody of desired 
antigen specificity, a mouse is immunized with the desired antigen and either the 
peripheral or splenic B cells are isolated (Figure 1.7). The pool of B cells is fused with 
myeloma cells and various cell-cell fusion products arise including B cell-B cell, 
myeloma-myeloma, and the desired B cell-myeloma hybrids as well as non-fused cells. 
These cells are then cultivated under specific conditions that allow only the growth of B 
cell-myeloma hybrids or hybridomas, each of which, in theory at least, should produce a 
single antibody protein. The hybridomas are serially diluted to isolate individual cells, 
and their secreted antibody is tested for binding toward the antigen used for 
immunization. A commonly used binding assay is an enzyme linked immunosorbant 
assay (ELISA) since it provides high-throughput parallel screening via multi-well plates. 
Hybridomas secreting antibodies of interest are collected, and their respective antibodies 
are expressed for further characterization and production if necessary. 
The hybridoma technology is still used today, but has several critical limitations 
(161). The immunization process required to engage the secondary immune response and 
generate the highest affinity antibodies in vivo is time consuming and difficult to 
parallelize (56). Further, the affinity of these antibodies is typically in the nanomolar 
range, but not necessarily in the picomolar range, which is required for many therapeutic 
antibodies (24, 105). Additionally, mouse antibodies induce an immune response when 
administered to humans since they are recognized as foreign molecules. This is referred 
to as the human anti-mouse antibody (HAMA) response. The HAMA response can 
results in rapid clearance and reduced efficacy of mouse therapeutic antibodies and also 
increases the risk of allergic reactions (77, 95, 122). In addition, mouse antibodies have 
difficulty initiating effector function in humans because of sequence differences in their 
Fc regions. 
 
Figure 1.7.  The hybrdidoma technology. 
The image is reproduced with permission from Nature (100). 
The use of Human B cells rather than those from mice could in principle be 
employed to generate human hybridomas. However, generating hybridomas from human 
B cells is much more difficult than it is from murine cells (41, 161). Even though many 
of these technical limitations have been overcome, there are obvious ethical reasons that 
prevent humans from being immunized to produce antibodies (95). Ethical complications 
can be avoided if the B cells are isolated from individuals who would normally be 
vaccinated or are naturally responding to an infection or disease, but this approach is only 
effective for a subset of diseases. Lastly, the majority of therapeutic targets for antibodies 
are human antigens, and the immune system has evolved to prevent the generation of 
 19
antibodies toward them to avoid autoimmunity through a process known as self tolerance 
(95). 
 
Figure 1.8.  The evolution of human antibodies. 
VectibixTM (panitumumab) became the first FDA approved therapeutic antibody 
generated from a transgenic animal in 2006, but it was not approved at the time this 




The risk of immunogenicity associated with therapeutic antibodies derived from 
mice is reduced by creating chimeric antibodies in which the mouse constant domains are 
replaced by their human counterparts (122, 129) (Figure 1.8). This approach removes 
two-thirds of the mouse sequence and simultaneously provides human Fc regions that 
more effectively engage the human immune system. Although there are several FDA 
approved chimeric antibodies, some chimeras generate a HAMA response resulting from 
the remaining mouse variable domains.  
The variable domains can be either de-immunized or further humanized through a 
variety of processes in order to further reduce their immunogenicity (122). Antibodies 
can be de-immunized by removing potential T-cell epitope sequences identified using 
bioinformatic techniques (122). However, such methods are unreliable at the moment. 
The more common approach is humanization by replacing the mouse framework regions 
with human ones through a process called CDR grafting (Figure 1.9). These approaches 
can result in a reduction of antibody affinity, which in turn necessitates the reengineering 
of affinity back into the antibody, a process that is time consuming. Regardless, 
humanized antibodies can be effective and account for half of the FDA approved 
antibodies (Table 1). 
       
Figure 1.9.  Humanization by CDR grafting. 
The image is reproduced with permission from Nature (100). 
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Transgenic Mice 
The inherent immunogenicity of mouse monoclonal antibodies and the limitations 
of human hybridomas has led to the engineering of transgenic mice that encode human 
immunoglobulin genes repertoires instead of their own (95). As a result these mice 
contain B cells that produce human antibodies. (57, 96). In these mice, the entire mouse 
heavy chain and kappa light chain genes were removed and most, but not all of the 
human heavy and kappa light chain genes were introduced in their place (Figure 1.10). 
Even though only a small fraction of the heavy chain variable domain gene repertoire is 
encoded by these transgenic mice, they generate antibodies toward a diverse array of 
antigens (95). 
 
   
Figure 1.10.  Transgenic mice germlines. 
The human heavy and light chain immunoglobulin germline gene segments configuration 
is depicted in the top row. The bars below represent the regions of the human germline 
that have been introduced into mice for the generation of human antibodies. The image is 
reproduced with permission from Nature (95). 
Transgenic mice now exist that contain the gene loci of the entire human heavy 
and kappa light chains (95). They are capable of generating completely human antibodies 
with affinities in the low- to sub-nanomolar range (77, 95, 127). The first approved 
therapeutic antibody generated from a transgenic mouse, VectibixTM (panitumumab), was 
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approved in 2006 and many others are in clinical evaluation (77, 95). Although 
transgenic mice have revolutionized the hybridoma technology by nearly eliminating 
immunogenicity, they still have similar limitations to hybridomas such as antibody 
affinity and the ability to generate antibodies toward certain molecules including human 
proteins that share a high degree of homology with their mouse counterparts. 
 
ANTIBODY DISCOVERY AND ENGINEERING IN VITRO 
Technologies for the discovery and engineering of antibodies in vitro are designed 
to mimic the in vivo generation and selection of antibody diversity accomplished by the 
immune system in a process known as directed evolution (70, 72). These in vitro 
approaches are more efficient and result in the discovery of a wider array of antibodies 
compared to hybridomas (72). Further, they circumvent the limitations of the natural 
immune system and can be used to discover antibodies toward any target including toxins 
and self antigens. They can also be used to improve a variety of antibody properties 
including specificity, affinity, stability, avidity, immunogenicity, effector functions, 
pharmacokinetics, pharmacodymanics, and expression level in heterologous systems for 
mass production. Regardless of the technology or its application, they all require the 
generation of sequence diversity and a selection platform for isolation (72).  
 
GENETIC DIVERSITY AND LIBRARY CONSTRUCTION 
Genetic diversity of the variable domains is typically created in vitro using gene 
amplification by the polymerase chain reaction (PCR) or by DNA synthesis (158). The 
resulting gene pools are referred to as a library. Libraries for discovery applications are 
classified as immune, naïve, or synthetic (Figure 1.11). Immune libraries are cloned from 
a donor immunized with a particular antigen, naïve libraries are cloned from a non-
immunized donor, and synthetic libraries are rationally designed by randomization of the 
amino acid positions typically involved in antigen binding as determined from known 
antibody sequence and structure data (72). The size of the library is critical, as larger 
libraries allow for greater sequence diversity to be represented, which increases the 
probability of isolating an antibody with desired properties (70, 75). 
 
 
Figure 1.11.  Sequence diversity for library construction. 
The sequence diversity at the center of the antigen binding site of an antibody is 
represented by each octagon. Within in each antigen binding site are the six heavy and 
light chain CDRs which are depicted as different regions. The origin of the CDR 
sequence is either natural (green) or synthetic (red) with darker shades indicating higher 
levels of diversity. Dots indicate either mutations from somatic hypermutation (green) or 
synthetic diversity (red). The image is reproduced with permission from Nature (72). 
The affinity of antibodies isolated from an immune, naïve, or synthetic library are 
often sufficient for analytical applications, but too low for a variety of therapeutic 
applications such as toxin and viral neutralization (19, 105). These antibodies must 
undergo the process of affinity maturation (Figure 1.11). As with somatic hypermutation 
in vivo, the antibody sequence can be mutated in vitro to obtain variants with different 
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amino acid sequences that confer an increase in affinity. Libraries are constructed by 
PCR or DNA synthesis using different mutagenesis strategies and are classified as 
targeted, error-prone, or shuffled (10). Targeted libraries randomize a small number of 
amino acid residues, frequently located in the complementarity determining regions 
(CDR), that are likely to interact with the antigen (10). These residues can be precisely 
determined based on a crystal structure of the antibody-antigen complex or based on 
general antibody sequence and structure data. Error prone libraries introduce random 
mutations across the entire gene. They are typically generated in vitro by PCR under 
conditions that randomly introduce mutations at a given rate across the entire gene, but 
can also be generated in vivo using mutator strains of E. coli (50, 97). This approach has 
led to the identification of sites critical for binding that are not structurally obvious and 
would not have been found from a targeted approach (92). The DNA sequences of 
several antibodies isolated from either of the previous libraries can be randomly digested 
then recombined by PCR to create a shuffled library. This approach has generated 
antibodies with drastically improved properties compared to the individual sequences 
from which they were derived (113). Finally, all of these strategies can also be used to 
enhance other antibody properties that have previously been mentioned. 
 
DISPLAY TECHNOLOGIES 
In order to efficiently isolate antibodies with desired properties from the 
enormous gene libraries described above, numerous display technologies have been 
developed (Figure 1.12) (72). In general, the systems that comprise these different 
technologies share three steps: a link between genotype and phenotype, application of a 
selective pressure, and amplification of the selected population (Figure 1.13) (72).  
        
Figure 1.12.  in vitro display technologies. 
The symbols are as follows: surface, black striations; antigen, red arrow; antibody, red 
rectangle with triangular recess; DNA, wavy red line; phenotype-genotype link, green 
line; proteins, green rounds shapes; surface, additional blue, green, or purple shapes. The 
image is reproduced with permission from Nature (72). 
By applying these steps, the small numbers of antibodies with desired properties 
are enriched from large libraries containing mostly undesirable antibodies through 
sequential rounds of screening followed by analysis of monoclonal antibodies produced 
by individual clones. The three most commonly used technologies are phage, microbial, 
and ribosome display (72). Phage display on the surface of filamentous bacteriophage is 
the most established screening system for antibodies as well as other proteins (135, 148). 
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Microbial display on the surface of bacteria or yeast cells such as E. coli and 
Saccharomyces cerevisiae, respectively, have become increasingly popular due to recent 
advances in flow cytometry (30, 37, 38, 53, 120). There are also several entirely in vitro 
display technologies of which the ribosome display system has been used with the most 
success (72). Much larger libraries can be constructed using entirely in vitro systems 
since they are not limited by the DNA transformation efficiency of cells. 
 
 
Figure 1.13.  in vitro selection process. 
The symbols are as follows: surface, black striations; antigen, red arrow; antibody, red 
rectangle with triangular recess; DNA, wavy red line; phenotype-genotype link, green 
line; proteins, proteins, green rounds shapes; surface, additional blue, green, or purple 
shapes. The image is reproduced with permission from Nature (72). 
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Phage Display 
The first technology used to display a functional antibody binding domain was 
phage display (109). Phage display is based on encoding the gene of interest in-frame with 
one of the phage coat proteins and encapsulating the fusion gene within the phage particle. 
The filamentous bacteriophages M13, fd, and f1 are the most commonly used phage 
particle (10, 135). They are approximately 1 um long and approximately 10 nm in 
diameter and are comprised of multiple copies of five different coat proteins which 
encapsulates the single stranded DNA genome (ssDNA) (Figure 1.14). The phage 
particles consist of about 3000 copies of the major coat protein (pVIII) which are capped 
on the ends by approximately 5 copies of each of the minor coat proteins (pIII, pVI, pVII, 
pIX) (135, 143).  
      
Figure 1.14.  Bacteriophage structure and composition. 
The image is reproduced with permission from Biomolecular Engineering (143). 
All of the coat proteins have been used to display recombinant antibody 
fragments, but pIII remains the most widely used since it is compatible with scFv, Fab 
and (F(ab’)2) display (6, 51, 52, 73, 90, 109, 135). The pIII protein is responsible for 
bacterial infection and fusions must be carefully made so infectivity can still proceed. 
They are frequently made at the N-terminus of pIII immediately after the leader peptide, 
but other variations do exist that also maintain infectivity (19, 87). Polyvalent display on 
all copies of pIII is achieved by cloning the antibody fragment gene in frame with the pIII 
gene located in the phage genome (109, 118). The DNA is transformed into E. coli and 
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phage particles displaying the fusion protein are subsequently produced. Phage vectors 
are difficult to work with since the phage genome is ssDNA, which makes the 
construction of large libraries difficult (19). The polyvalent display results in avidity 
effects leading to the isolation of a greater diversity of antibodies, but at the expense of 
lower affinity antibodies (19). This also makes affinity maturation difficult since a small 
increase in affinity can not out-compete the avidity effect (19). These issues are 
circumvented by cloning the antibody fragment gene in frame with the pIII gene using a 
double stranded DNA (dsDNA) plasmid vector known as a phagemid (109, 118). 
Phagemids do not contain any other genes from the phage genome, but they do contain 
the origin of replication and packaging signal from it. E. coli is transformed with the 
phagemid and subsequently infected with helper phage that provides the necessary genes 
for replication and preferential packaging of the phagemid as ssDNA inside the phage 
particle. The native pIII encoded by the helper phage genome out competes the non-
native antibody-pIII fusion and results in lower levels of fusion display. This display is 
frequently monovalent and allows the selection of higher affinity antibodies since there is 
no avidity effect (19). 
Phage display has been used to isolate antibodies from immune, naïve, or 
synthetic libraries and engineer them for improved properties including affinity and 
stability (72). Antibodies are selected from these libraries through a process called 
panning (Figure 1.15). Through this process, the target antigen is immobilized on a 
surface and phage displaying antibodies specific for the antigen are isolated through 
sequential rounds of adsorption, desorption, and amplification of the phage. Variations of 
this process exist in order to isolate antibodies with specific properties, but the concept 
remains the same (10, 71). HumiraTM (adalimumab, the first fully human mAb to receive 
FDA approval, was discovered using phage display (154). Currently, there are at least 16 
human mAbs derived from phage display in advanced clinical trials for a wide range of 
human diseases (81, 119, 129, 154).  
 
 
Figure 1.15.  Phage panning process. 
The image is reproduced with permission from Nature (100). 
 
Microbial Display 
Antibodies can also be displayed on the surfaces of cells to maintain a link 
between genotype and phenotype (Figure 1.12). Microbial display on the surface of 
bacteria or yeast cells, most commonly E. coli and S. cerevisiae, is typically used because 
of their faster growth rates, higher transformation efficiencies, and lower production costs 
compared to mammalian cells. Microbial display has one clear advantage over phage and 
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ribosome display, namely the ability to utilize fluorescence activated cell sorting (FACS) 
(38, 63). FACS is a high-throughput screening technique that enables real-time 
quantitative multi-parameter analysis on a cell by cell basis. Therefore, multiple 
properties can be monitored simultaneously to specifically isolate antibodies with desired 
characteristics such as antigen binding and high antibody expression levels. 
 
Flow Cytometry 
Flow cytometry is a high-throughput technique used to individually analyze 
microscopic particles based on their physical and chemical characteristics (Figure 1.16). 
The most sophisticated flow cytometers are capable of analyzing 109 cells/hr and can be 
used to isolate extremely rare events present at frequencies of less than one in a million 
(37, 89). In flow cytometry, a narrow, hydrodynamically focused stream of fluid 
containing the suspended particles in a single file orientation flows through an 
interrogation chamber in which one or more beams of light, typically lasers, are focused. 
For each particle, the extent of light scattering and fluorescence emission at different 
wavelengths are measured by separate detectors to enable multi-parameter analysis. The 
light scattering determines relative size (FSC) and internal complexity of the particle 
(SSC) while the fluorescence emissions are used to detect particular properties of the 
particle. The number of parameters capable of being analyzed simultaneously is 
dependent upon the number of lasers and detectors with which the flow cytometer is 
equipped (141). 
There are numerous fluorescent molecules available that can be used either 
independently of or in conjunction with non-fluorescent molecules to determine an 
overwhelming amount of intracellular and extracellular information about a given cell 
(103, 141). This includes the presence of surface markers, cell viability, pH, and 
membrane potential. Cells can be simultaneously labeled with multiple fluorophores as 
long as their spectral characteristics are compatible for simultaneous detection. 
Simultaneous detection of 13 different cellular parameters has been reported (121).  
Following labeling of a heterogeneous cell population to identify individual cells 
with particular characteristics, specialized flow cytometers can be used to individually 
select these cells through a process known as fluorescence activated cell sorting (FACS) 
(93, 103). For example, antibodies displayed on the surface of cells can be 
simultaneously labeled to determine their ability to bind one particular antigen over 
another and their expression levels (17). Cells displaying antibodies with desired 
characteristics are diverted into a collection tube by a mechanical or electrical device 















































































The display of proteins from the outer membrane seems to be the most obvious 
choice for a cell surface display system. In 1986, peptides were first displayed on the 
surface of E. coli by inserting them into the external loops of endogenous outer 
membrane proteins (27, 49). However, inserting large proteins into the external loops 
often interferes with localization of the fusion protein and therefore unsuccessful display 
(53). This problem was overcome and the potential of bacterial surface display as a 
means to isolate antibodies of desired specificity through FACS was demonstrated with 

























The Lpp-OmpA tribrid system was designed based on the specific properties of 
the E. coli major lipoprotein (Lpp) and outer membrane protein A (OmpA) (43). Lpp is 
an outer membrane lipoprotein localized to the periplasmic face of the outer membrane 
and is critical for efficient localization of the heterologous protein to the outer membrane 
(43). OmpA is an outer membrane protein consisting of eight membrane-spanning anti-
parallel β-strands forming a β-barrel structure and is responsible for displaying the 
protein of interest on the surface of the cell (43). Independently, neither system 
appropriately displays fusions proteins on the bacterial surface, but a combination of the 
signal sequence and first nine amino acids of Lpp with a truncated form of OmpA 
enables successful display on the surface of E. coli as an Lpp-OmpA fusion (Figure 1.17) 
(43, 47, 54, 55). 
Antibody engineering with the Lpp-OmpA system has been limited to single 
chain antibody fragments (scFv) directed against low molecular weight antigens such as 
the hapten digoxigenin. It has been used on multiple occasions to affinity mature a 
digoxigenin specific antibody and can be used to quantitatively discriminate between 
mutants that vary in affinity (36, 37). However, most antibodies target higher molecular 
weight antigens, such as proteins, and there are no reported cases of the display of 
antibodies specific for larger antigens on the surface of E. coli using Lpp-OmpA. 
Although protein specific antibodies have not been displayed on E. coli, they have 
been displayed on the surface of the Gram-negative bacteria Salmonella typhimurium 
(11). OmpA is highly conserved among Enterobacteria and the Lpp-OmpA system is 
compatible with them (32). The Lpp-OmpA system was used to display an antibody 
specific for the carcinoembryonic antigen (CEA) on the surface of the S. typhimurium 
and was used for tumor targeting in vivo (11). The utility of the Lpp-OmpA system has 
been demonstrated for various applications, but future work is needed to determine the 
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robustness of the system for broader antibody engineering applications (3, 4, 22, 34, 46-
48, 82, 134, 142, 151, 155-157). 
 
PECS 
In order to display an antibody on the surface of a biological particle, it is 
typically required to create a fusion between the antibody and a surface protein. This can 
alter the inherit stability of the antibody. For example, it is frequently observed that scFvs 
isolated as fusions using phage display do not function when expressed on their own (78). 
It is rarely beneficial to isolate antibodies that are only stable when expressed as a fusion 
since the antibody will need to be function on its own for most applications (64). 
Therefore, it is beneficial to have a display system that does not rely on the creation of an 
antibody fusion protein and at the same time retains the link between genotype and 
phenotype. 
Periplasmic expression with cytometric screening (PECS) is an innovative fusion-
free system that enables the selection of antibody fragments toward low molecular weight 
targets (Figure 1.17) (29). Through a combination of bacterial strains, growth conditions, 
and incubation with antigen under high osmotic conditions, scFvs expressed in the 
periplasm of E. coli can be specifically labeled with fluorescently conjugated antigen up 
to 10 kDa in size then detected by flow cytometry. This process increases the diffusion 
limitations of the outer membrane by over an order of magnitude while minimally 
compromising cell viability (29, 132). PECS was used to affinity mature the anti-
digoxigenin scFv previously used with the Lpp-OmpA surface display system (28, 36, 
37, 39, 46). 
A convenient aspect of PECS is its amenability for use with existing phage 
display libraries. Many phage display vectors contain an amber codon located between 
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the 3’ end of the scFv gene and the 5’ end of the pIII phage coat protein gene used for 
displaying the scFv from the phage particle. Incomplete suppression of the amber codon 
results in early translation termination following scFv synthesis so the fusion partner is 
not expressed. This leads to soluble scFv in the periplasm of E. coli which is then suitable 
for screening by PECS. A combination of this approach and phage panning was used to 
isolate anti-digoxigenin specific scFvs from the semi-synthetic Griffin library (29). 
Interestingly, a high expressing scFv was isolated by PECS that behaved poorly when 
expressed as a pIII fusion on phage. This result demonstrates how the behavior of a scFv 
can be affected when expressed as a fusion partner in a display system and why fusion-
free approaches may be better suited for antibody engineering. 
The PECS system has also been used in a genetic selection to isolate a faster 
folding scFv variant (132). A library of anti-digoxigenin scFv mutants were expressed in 
the cytoplasm of an oxidizing strain of E. coli to enable proper folding and disulfide bond 
formation. They were fused a leader peptide specific for the twin arginine translocation 
(Tat) pathway, which requires proteins to be folded prior to export from the cytoplasm to 
the periplasm (91). Selection for binding toward digoxigenin using PECS resulted in the 
isolation of a mutant scFv with the same affinity, but exhibited faster folding, which led 
to higher export efficiency. This is a great example of how existing systems can be used 
to isolate antibodies with unique properties. 
 
APEx 
An alternative to displaying proteins on the outer membrane of Gram-negative 
bacteria is to display them on the inner membrane. Anchored Periplasmic Expression 
(APEx) is a system that anchors proteins to the periplasmic face of the inner membrane 
of E. coli (Figure 1.17) (59). The major advantage of APEx over other E. coli display 
systems is the displayed antibody can interact with much larger antigens following 
disruption of the outer membrane and peptidoglycan layer by chemical and enzymatic 
means (29, 36, 37, 39, 46, 59, 132). APEx has been used for the affinity maturation of 









































































Figure 1.18.  APEx antibody display and selection process. 
A schematic diagram of anchored periplasmic expression (APEx). Depicted is the 
original system displaying a scFv antibody fragment reengineered to display a C-terminal 
epitope peptide sequence (FLAG) to account for simultaneous detection of antigen 
binding and antibody expression levels. 
In APEx, antibody fragments are anchored onto the periplasmic side of the inner 
membrane via fusion to either a transmembrane domain of an integral membrane protein 
or to the signal peptide and the first few N-terminal amino acids of an inner membrane 
lipoprotein, such as new lipoprotein A (NlpA) (59, 79). The latter anchoring strategy is 
usually preferable because lipoprotein fusions can be expressed at higher levels. 
However, C-terminal fusions between the antibody and the pIII minor coat protein from 
M13 bacteriophage enables existing phagemid libraries to be used with the APEx system 
without the need for DNA manipulations, as is the case with PECS. For the detection and 
subsequent isolation of antigen specific antibody fragments, the cells are converted to 
spheroplasts through chemical and enzymatic means in order to disrupt the outer 
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membrane and peptidoglycan layer, incubated with a fluorescently labeled antigen, and 
isolated by fluorescence activated cell sorting (FACS) based on high fluorescence (Figure 
1.18). Molecules up to 400 kDa in size have been used and hence most soluble proteins 
are compatible with the system (80). 
APEx has been used for the affinity maturation of two different single chain 
antibody fragments (scFv) as well as to engineer scFvs that fold in the absence of 
disulfide bonds (59, 60, 140). Variations of APEx have been developed based on having 
anchored proteins specifically interact with soluble proteins in the periplasm prior to 
conversion to spheroplasts, which allows the unassociated proteins to diffuse away so 
only specific interactions are detected (Figure 1.17). This approach has been used to test 
the interaction between an anchored scFv and soluble peptide antigen fused to GFP, to 
affinity mature a scFv by simultaneously expressing its antigen in the periplasm, and to 
engineer a higher expressing Fab by co-expressing an anchored light chain (VL-CΚ) and a 
soluble heavy chain (VH-CH1) (59, 80). It has also been used to engineer the first full-
length antibody (IgG) display system for the isolation of antibodies from combinatorial 
libraries expressed in E. coli, which is referred to as E- clonal (108). 
It is important to note that E. coli is no longer viable following conversion to 
spheroplasts. Therefore, the antibody encoding DNA from cells isolated by FACS must 
be recovered by PCR and re-cloned into the appropriate vector for subsequent rounds of 
selection or soluble monoclonal antibody screening. This process has the disadvantage of 
increasing the duration of each round of sorting, but it can also be advantageous (59). For 
example, the PCR step can be performed under mutagenic conditions to enhance directed 
evolution and the isolation of higher affinity antibodies.  
 
Yeast Surface Display 
Although phage display is the oldest and still dominant antibody display system, 
yeast surface display is becoming increasingly popular and is the most widely used 
microbial display system (17, 72). Antibodies are typically displayed on the surface of S. 
cerevisiae by creating an N- or C-terminal fusion to the Aga2p mating adhesion receptor, 
which naturally forms disulfide bonds with Aga1p and anchors the complex to the cell 
wall (Figure 1.19) (120). Functional scFvs and Fabs have both been displayed on the 
surface of yeast, with the latter being accomplished by anchoring the heavy chain which 
then captures the soluble light chain (120). Antigen binding is simultaneously monitored 
with antibody expression levels by fluorescent labeling of an epitope peptide located on 
the C-terminus of the antibody fusion protein (17). This enables antigen binding per 
antibody to be normalized and cells displaying the highest affinity antibodies can be 
isolated by FACS. This system has been used to isolate and engineer antibodies toward a 
wide array of antigens ranging in affinity from micromolar to femtomolar (1).  
      
Figure 1.19.  Yeast surface display. 
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Antibody fragment binding toward a biotintylated antigen is detected by fluorescently 
conjugated avidin. Antibody expression levels are simultaneously detected by a 
fluorescently conjugated antibody specific for the c-Myc epitope peptide. Appropriate 
fluorophores are used for detection by flow cytometery. Hemagglutinin (HA) is an 
alternative marker for surface display detection. The image is reproduced with permission 
from Nature (26). 
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Ribosome Display 
The major drawback to phage display and cell display is the ability to generate 
large libraries because of limitations in transformation efficiency, the ability of a cell to 
uptake and maintain exogenous DNA. Ribosome display, however, is an entirely in vitro 
display technology and since library size is independent of transformation efficiency, 
they can easily exceed 1013 different genes (42). The genes are transcribed and translated 
using cell-free expression systems which contain cell lysates to supply the necessary 
enzymes and machinery for protein synthesis and are supplemented with additional 
components such as nucleotides, amino acids, and energy-generating factors (76). 
Recently, cell-free systems have been reported that use entirely purified components 
(152). 
In ribosome display, a gene pool encoding the desired sequence diversity is 
generated in vitro, typically by PCR, and then the respective proteins are synthesized. In 
order to maintain the link between the genotype and phenotype, an identical spacer 
sequence lacking a stop codon is cloned in frame at the 3’ end of the antibody gene 
(Figure 1.20) (164). This allows the antibody to properly fold outside the ribosome 
tunnel, but prevents the ribosome, mRNA, and antibody fragment complex from being 
disrupted. This complex is further stabilized by lower temperatures and the addition of 
magnesium ions, and the displayed antibodies are selected in a process analogous to 
phage panning (42). The mRNA encoding the isolated antibodies is converted into cDNA 
by reverse transcription, which is amplified by PCR into DNA so the process can be 
repeated (10). A major drawback to ribosome display is the conditions for selection 
cannot interfere with the stability of the ribosome complex. This prevents engineering 
antibodies toward certain antigens or generating thermally or chemically resistant 
antibodies. 
 
   
Figure 1.20.  Ribosome display. 
They symbols are as follows: T7, T7 RNA polymerase promoter; RBS, ribosome binding 
site; F, FLAG epitope peptide. The image is reproduced with permission from Drug 
Discovery Today (164). 
Ribosome and the other in vitro systems are well suited for affinity maturation of 
antibodies because of the inherit directed evolution resulting from in vitro recovery and 
amplification of the DNA sequence (72). This process can be subjected to conditions 
which add genetic diversity to the recovered antibody genes to further increase their 
affinity. Ribosome display is becoming increasingly popular for this application and 
numerous antibodies have been successfully engineered to have higher affinities (72). 




This dissertation describes the implementation of APEx for the discovery and 
engineering of antibodies with unique binding properties. It was used to isolate a small 
panel of antigen specific antibodies specific for the Protective Antigen (PA) component 
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from Bacillus anthracis, the causative agent of anthrax (125). It was also used to affinity 
mature an antibody specific for the V antigen of Yersinia pestis, the etiologic agent of the 
plague (149). Background information on each of these bacterium and their particular 
antigens is described below. 
 
Protective antigen (PA) from Bacillus anthracis 
The causative agent of anthrax is the spore forming, Gram-negative bacteria B. 
anthracis. It is an attractive biowarfare agent because it has a mortality rate of up to 80% 
and can penetrate the human body through skin, inhalation, or ingestion (112). Following 
entry into the body, B. anthracis spores germinate into vegetative bacteria that secrete a 
tripartite exotoxin that is responsible for disease etiology. The protective antigen (PA) 
component binds to one of two host cell receptors then undergoes proteolytic cleavage by 
a furin-like protease. It then undergoes a conformational change, which heptamerizes on 
the cell surface and binds either of the two remaining components, namely LF (lethal 
toxin) and EF (edema toxin). The complex facilitates entry of LF or EF into the cell 
through endocytosis (Figure 1.21). Once the toxins reach the cytosol, they begin to 
catalyze reactions that can ultimately lead to death (125). 
Numerous antibodies specific for all three components of the exotoxin have been 
isolated, but very few have therapeutic properties (20, 92). In order to prevent anthrax 
intoxication, the antibodies must prevent PA from binding to the cell surface receptors or 
disrupt toxin assembly (125). For example, affinity matured versions of one particular 
antibody that is known to prevent the PA receptor interaction from occurring are useful 
prophylactic and toxin neutralizing therapeutics for in vivo anthrax toxin challenges (59, 
94, 98, 105). However, single point mutations in PA can drastically reduce the 
neutralizing capabilities of these antibodies (138). Therefore, it is critical to isolate 
additional neutralizing antibodies for anthrax. 
  
Figure 1.21.  Anthrax toxin etiology. 
PA83 binds to either of two surface receptors (ATR or CMG2) and is cleaved by a furin-
like protease to give rise to PA63 and PA20. PA63 heptamerizes to form a prepore, which 
induces endocytosis following binding toward lethal factor (LF) or edema factor (EF). 
Acidification of the endosome LF or EF to enter the cytosol of the host cell resulting a 
biochemical cascade that can lead to death. The image is reproduced with permission 
from Nature (125). 
 
Virulence (V) antigen from Yersinia pestis 
Y. pestis is the etiologic agent of the plague and has been responsible for the 
pandemic outbreaks occurring throughout the course of history. Today, the most probable 
cause of an outbreak would be the use of Y. pestis as a biological weapon. There are three 
forms of the plague, namely pneumonic, bubonic and septicemic. Of these, the 
pneumonic plague is the most dangerous because it highly contagious through person-to-
person contact. Antibiotic treatments exist, but the mortality rate associated with 
pneumonic plague is nearly 100% if treatment is delayed more than 24 hours post-
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exposure (165). Even if treatment begins early enough, there are antibiotic resistant 










Figure 1.22.  Role of V antigen in plague pathogenesis. 
The V antigen mediates translocation of effector proteins (Yops) into host macrophages 
via a type III secretion system. The V antigen also has immunosuppressive functions 
following release from Y. pestis. The image is reproduced with permission from Julie 
Boyer (18). 
Vaccines and antibody therapies are attractive alternatives to antibiotic treatments 
(18). Plague vaccines are under development, but none are currently available in the US. 
The most promising vaccines are subunit vaccines based on the F1 capsular protein and 
the V antigen virulence factor. The V antigen plays a central role in plague pathogenesis 
(Figure 1.22). It activates a type III secretion system and through this it mediates 
translocation of the effector proteins known as Yops into macrophages located in the 
host. It is also released from the bacteria where it has immunosuppressive functions by 
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increasing levels of the anti-inflammatory cytokine interleukin 10 and decreasing levels 
of the inflammatory cytokine tumor necrosis factor alpha (147). Passive immunization 
with monoclonal antibodies (mAb) specific for the F1 capsular protein and the V antigen 
are attractive alternatives to vaccines and have been shown to be effective against lethal 








IgG or scFv Library Screening? A Comparison of                         
Antibodies Isolated by Bacterial Display 
 
INTRODUCTION  
Thanks to the development of high throughput screening techniques for the 
isolation of binding proteins from large libraries, it is now possible to isolate antibodies 
to virtually any antigen using in vitro methodologies. In vitro isolation of antibody 
fragments with desired specificity relies on the screening of large combinatorial libraries 
using display technologies that link an antibody gene to the respective protein, which is 
anchored or displayed on the surface of a biological particle such as a prokaryotic or 
lower eukaryotic cell, virus, or ribosome (2, 8, 106, 122).These methodologies were 
predicated on expression of heterologous proteins in microorganisms which are easy to 
genetically manipulate.  
Because early attempts to express soluble, full-length IgG in E. coli had been 
unsuccessful (157) in vitro, antibody isolation has relied on the use of antigen binding 
fragments such as the scFv, Fab, F(ab’)2, or single VH or VL domains, all of which can be 
expressed in bacteria with relative ease. Fab and scFv fragments usually maintain the 
binding specificity and affinity of their full-length IgG counterparts. Since they are much 
smaller than IgG, they display superior tissue biodistribution and rapid blood clearance. 
Antibody fragments have been fused together with other proteins, such as toxins or Fc 
domains, to yield molecules with desirable targeting, bioactivity, or biodistribution 
properties for a variety of therapeutic applications (70). Alternatively, the VH and VL 
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domains can be reformatted as IgGs, expressed in mammalian cells, and used for any 
therapeutic or other application requiring full-length immunoglobulins. 
Our lab has developed technologies for the screening of antibody fragment or, 
more recently, full-length IgG libraries, by capitalizing on E. coli inner membrane 
display and screening by fluorescence activated cell sorting (FACS). In anchored 
periplasmic expression (APEx), antibody fragments are anchored onto the periplasmic 
side of the inner membrane via fusion to either a transmembrane domain of an integral 
membrane protein or to the signal peptide and the first few N-terminal amino acids of an 
inner membrane lipoprotein, such as NlpA (59, 79). The latter anchoring strategy is 
usually preferable because lipoprotein fusions can be expressed at higher levels. For the 
isolation of antigen specific antibody fragments, the cells are converted to spheroplasts in 
order to disrupt the outer membrane and peptidoglycan layer, incubated with a 
fluorescent labeled antigen, and isolated by FACS based on high fluorescence. 
For the isolation of IgG, full-length heavy and light chains are expressed from a 
dicistronic operon and are secreted into the periplasm where they assemble into 
aglycosylated IgGs that are fully functional for antigen binding (106). The IgG is co-
expressed with the ZZ domain from Staphylococcus aureus protein A using APEx, which 
serves to non-covalently capture the antibody molecule onto the inner membrane. Then, 
the cells are converted to spheroplasts and clones that bind to fluorescently labeled 
antigen are isolated by FACS, as above. The resulting IgG protein can be expressed 
directly at the preparative level in E. coli and used directly for immunohistochemistry or 
in vivo animal studies. Another potential advantage of IgG library screening is that their 
higher avidity and stability may result in the isolation of a higher diversity of VH and VL 
domains relative to what could be obtained by screening the same antigen binding site 
diversity in a monovalent format. Consistent with this hypothesis, it has been shown that 
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the bivalent display of antibody fragments as F(ab’)2 molecules on the surface of 
filamentous bacteriophage enables the selection of a broader spectrum of antibodies (7, 
90).  
In this study, we sought to compare and evaluate the antibody binding sites that 
are isolated when the same library of VH and VL domains obtained from an immunized 
mouse is displayed as either IgGs or scFv fragments. The VH and VL genes were 
constructed by RT-PCR from splenocytes obtained from a mouse immunized with the 83 
KDa protective antigen (PA83) from Bacillus anthracis, the causative agent of anthrax. 
Following entry into the body, B. anthracis spores germinate into vegetative bacteria that 
secrete a tripartite exotoxin that is responsible for disease etiology (124). PA83 binds to 
one of two host cell receptors then undergoes proteolytic cleavage, which results in a 63 
kDa form (PA63). PA63 heptamerizes into a complex that facilitates entry of lethal factor 
and edema factor into the host cell by endocytosis and can ultimately lead to death. As a 
result, antibodies toward both PA83 and PA63 are potential therapeutic and diagnostic 
reagents (127). IgG and scFv (VL-VH and VH-VL) immune libraries were screened by 
APEx using essentially identical conditions. We show that the IgG library resulted in a 
greater diversity of VH and VL domains that conferred a broad range of antigen affinities 
(KD=21-440 nM). We show that the isolated variable domains demonstrated format 
dependent expression levels and affinities following conversion between antibody 
formats (IgG, VL-VH scFv, and VH-VL scFv). The results of this study illustrate how 
libraries of VH and VL domains in different formats result in the selection of antibody 




Library construction and screening 
VH and VL genes were generated by RT-PCR from mRNA isolated from 
splenocytes originating from a mouse that was immunized with Bacillus anthracis PA. 
Overlap extension PCR of the VH and VL gene pools was used to construct two scFvs 
libraries: a VL-VH library and a VH-VL library. A (Gly4Ser)4 linker was used to join the 
variable heavy and variable light domains in both libraries. 1 X 107 and 2 X 107 
transformants were obtained with the VL-VH and VH-VL libraries, respectively. Analysis 
of 10 clones from each revealed a high degree of sequence diversity in the variable 
domains (data not shown).  
The two libraries were pooled at a 1:2 ratio (VL-VH:VH-VL) to account for the 
difference in the number of independent transformants, the cells were grown in liquid 
culture, expression of NlpA-scFv protein was induced by adding IPTG, and they were 
converted to spheroplasts through chemical and enzymatic means (59).  A total of 2 X 
108 spheroplasts (>5-fold library coverage) labeled with 200 nM PA63-FITC were 
subjected to high-throughput fluorescence activated cell sorting (FACS). Approximately 
2% of the cells were collected based on binding to PA as determined by high FITC 
fluorescence emissions (Figure 2.1). The spheroplasts were immediately resorted as 
above without additional labeling to maximize the isolation of antibodies specific for PA 
(59). The scFv genes from the cells collected during the resort were amplified by PCR 
since the viability of cells undergoing conversion to spheroplasts is low (59). The PCR 
product of the entire round I gene pool was cloned into pAPEx1 for additional rounds of 
sorting as follows: (i) four additional rounds using decreasing concentrations of PA63-
FITC down to 40 nM in an attempt to isolate higher affinity clones; (ii) one additional 
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round using 400 nM PA83-BODIPY in an attempt to isolate antibodies that cross react 
with both forms of the PA antigen. 
 
Figure 2.1.  Schematic diagram of 
two APEx display systems. 
Libraries of either IgG (E-clonal) or 
antibody fragments (APEx) are 
expressed in the periplasm of E. coli. 
The antibody fragments are expressed 
from a single plasmid (pAPEx1) as 
fusions to NlpA(1-6) and are 
anchored to the periplasmic face of 
the cytoplasmic membrane. The 
heavy and light chains of the IgG are 
expressed as soluble proteins from a 
single plasmid (pMAZ360-IgG). The 
IgG antibodies assemble in the 
periplasm then are captured by the Fc-
binding protein ZZ that are expressed 
from a second plasmid (pBAD33) as 
fusions to NlpA(1-6). The cells are 
converted to spheroplatst through 
chemical and enzymatic degradation 
of the outer membrane and 
peptidoglycan layer allowing 
fluorescently labeled exogenous 
antigen to interact with the antibodies 
displayed on the surface of the inner 
membrane. Spheroplasts containing 
antibodies specific for the antigen are 
enriched from the total population by 
FACS and their antibody genes 
recovered by PCR. NlpA(1-6), new 
lipoprotein A (NlpA) leader peptide 
plus first six amino acids of the 
mature lipoprotein; CDQSSS, NlpA 
amino acids 1-6; ZZ, synthetic 
analogue of the IgG binding B domain 
of the Staphylococcus aureus protein 
A. 
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ScFv genes from various rounds of scFv library sorting were directly cloned into 
pMoPac16 for soluble scAb protein expression then direct binding via ELISA. The scAb 
format is comprised of a scFv in which the C termini of the variable light chain domain is 
fused to the human kappa constant domain (HuCΚ), resulting in improved expression 
characteristics in E. coli without altering the antibody binding affinity (62). 
Approximately 400 clones were individually picked and the monoclonal scAbs they 
encoded for were expressed using 96-well microtiter plates. Lysates were individually 
analyzed for binding toward PA83 via ELISA. Of all the clones tested, only 2 showed 
significant binding (>5-fold above background) (106). DNA sequencing revealed that one 
of the isolated anti-PA scFvs, B12, was oriented VL-VH and the other, C9, was oriented 
VH-VL. Further analysis indicated that these two VH and VL domains originated from 
different germline genes (Table 2.1).  
Table 2.1.  Variable domain germline gene sequencesa 
Antibody Heavy Chain Antibody Light Chain 
H2b, B12c J558.18 H2b, C3b ce9 
D1b, F10b VHSM7.a4.108 B2b, D1b, F10b 19-23 




aV gene segment determined using IgBlast from NCBI 
bIsolated as an IgG 
cIsolated as a VL-VH scFv 
d Isolated as a VH-VL scFv 
 
Five unique anti-PA clones (B2, C3, D1, H2, and F10) were previously isolated as 
full-length IgG antibodies from a combinatorial library constructed from the same cDNA 
and selected by FACS (106). Within this group, there were four different VH and two 
different VL germline genes (Table 2.1). Both of these VL germlines were different from 
those of the scFvs, but two of VH germlines were identical. The VH domains of C3 and 
C9 only differed in 2 amino acids, but those of H2 and B12 differed by 13 amino acids of 
which 6 were in CDRs (Figure 2.2). In total, four different VH and four different VL 
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Figure 2.2.  Amino acid sequence analysis of the antibody variable domains. 
Anti-PA antibodies isolated using APEx or E-clonal systems. Frameworks (FW) and 
complementarity determining regions (CDR) based on Kabat numbering (102). 
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Variable domain format comparison 
The anti-PA IgG variable domain genes were converted to both scFv orientations 
(VH-VL and VL-VH) and cloned into pMoPac16 for scAb protein expression. Similarly, 
the anti-PA scFv variable domain genes were converted to the scFv orientation opposite 
to that of which they were isolated as well as to IgG format and cloned into the 
appropriate vectors for scAb and IgG protein expression (see Figure 2.3A). The relative 
expression level of the 21 proteins encoded by these 21 antibody constructs was 
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Figure 2.3.  Variable domains format dependent expression levels. 
Format dependent expression levels of antibodies as determined by Western blot analysis. 
(A) Schematic diagram depicting the conversion of the isolated antibodies from one 
format to another. Western blot analysis of the antibodies expressed as (B) scAbs and (C) 
IgGs. Some antibodies were (+) and others were not (-) able to be purified from large 
scale cultures. *format of the antibody as it was originally isolated. N, N-terminus; C, C-
terminus; HL, VH-VL; LH, VL-VH; MW, molecular weight; IgG, 10 ng of IgG isolated 
from human serum 
The relative expression level of the scAbs varied from less than 10 ng/L (B12 VH-
VL and B2 VH-VL) to over 1 mg/L (F10 and D1) and was dependent on the orientation of 
the variable domains for each of the seven antigen binding sites. As expected, the 
expression of both B12 and C9 was detectable in the scFv orientation they were isolated 
in. However, the expression level of B12 was undetectable and C9 was expressed 
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significantly lower when the orientations of their variable domains were switched. Even 
though B12 and B2 were both undetectable as VH-VL scAbs, B2 could be expressed to 
purifiable quantities from two liters of culture volume while B12 was not. The highest 
expressing scAbs were originally isolated as IgGs (F10 and D1), but the remaining IgGs 
typically expressed poorly as scAbs regardless of their variable domain orientations.  
As with the scAbs, the relative expression levels of the IgGs was highly variable. 
Five of the seven expressed fully assembled IgG (see Figure 2.3C). One of these five is 
C9, which was originally isolated as a scFv. Even if the antibodies originated from same 
the germline gene sequences for both variable domains, their relative protein expression 
levels were still format dependent. For example, both D1 and F10 share the same VH and 
VL germline genes, the proteins they encode for are only different by 9 amino acids in 
total, they both express very well as scAbs in both orientations, but only D1 expresses 
very well as an IgG. 
Monomeric scAb and full-length IgG proteins were expressed and purified from 
up to two liters of culture volume in order to obtain enough protein for antigen binding 
studies. As was previously stated, B12 VH-VL scAb and IgG proteins could not be 
purified following multiple attempts and therefore binding studies could not be 
performed with them. Detailed analysis of the binding kinetics toward both PA83 and 
PA63 using surface Plasmon Resonance (SPR) was performed for all clones that could be 
expressed. The SPR results for each antibody in the format in which they were originally 
isolated are shown (Table 2.2). C9 was isolated as a VH-VL scFv and exhibited the 
highest affinity at 6 nM. B2 was isolated as an IgG and exhibited the lowest affinity at 




Table 2.2.  Binding kinetics of isolated antibodies determined by SPR 
Antibody Isolated Format 
Ka             
(M-1s-1) 
kd            
(s-1) 
KD           
(nM) 
H2b IgG 1.3 X 106 2.7 X 10-2 21 
F10a IgG 4.9 X 105 1.5 X 10-2 31 
C3b IgG 6.8 X 105 3.2 X 10-2 47 
D1a IgG 3.5 X 105 1.9 X 10-2 55 
B2a IgG 3.2 X 104 1.4 X 10-2 440 
C9b VHVL 1.5 X 105 9.0 X 10-4 6 




Some clones could not be analyzed by SPR due to a combination of low affinities 
and low protein yields following expression and purification. Therefore, the apparent KD 
of each antibody toward both PA83 and PA63 were determined by ELISA half-maximal 
binding (Figure 2.4). Antibodies that exhibited very poor binding did not reach saturation 
in the ELISA assays even at the highest concentration used (4 μM) (Figure 2.5B). For 
these antibodies, the KD values were calculated using a non-linear optimization approach 
based on the ELISA data and equilibrium kinetics (Figure 2.5C) (26). The validity of this 
approach was proven by obtaining similar KD values to those that were obtainable by 
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Figure 2.4.  Variable domains format dependent specificity and affinity. 
Radar plots indicating the affinities of each antibody as determined by ELISA. Each of 
the three axes represents a different antibody format. Dots on each axis indicate the KD 
against PA83 (red) or PA63 (blue). The outer most, middle and center vertexes indicate 
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Figure 2.5.  Antibody apparent affinity determination by ELISA. 
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Examples of (A) complete and (B) incomplete ELISA data generated for two different 
antibodies and used to calculate the KDs by a non-linear optimization approach. ELISA 
data was generated from the average of duplicate runs. The non-linear optimization 
approach was previously used to determine the affinities of yeast surface displayed 
antibody fragments by flow cytometry (26). (C) Equilibrium equation that the ELISA 
data should fit (26). (D) Comparison of KDs determined by ELISA and SPR for two 
different antibody formats. ELISA KDs were generated from the data in (A) and (B). 
The affinity and specificity results determined by ELISA and SPR are 
summarized as Venn diagrams for both PA83 and PA63 (Figure 2.6). The affinities of the 
variable domains in different formats for either PA83 or PA63 were considered equivalent 
if they were within 5-fold of each other. Overall, we observed a high degree of variation 
in the binding behavior of these seven antigen binding sites when expressed as different 
antibody formats. Only one of the antibodies (C9) binds to a given antigen (PA83) with 
the same affinity independent of the format. Interestingly, the VH domains of C3 and C9 
only differed in 2 amino acids. However, the VL domains of these antibodies were 
derived from different germline sequences and this might have affected their expression 
properties and possibly the affinity. Expression levels did not correlate with affinities 
either. For example, F10 expresses very well in both scAb formats, but the affinities are 
over 10- and 100-fold lower than the IgG format. However, B2 VH-VL was amongst the 





















Figure 2.6.  Summary of antibody specificity and affinity. 
Venn diagrams summarizing specificity and affinity of the anti-PA antibodies in different 
variable domain formats as determined by SPR and ELISA. Each circle represents a 
different antibody format as follows: VH-VL (green), VL-VH (yellow) and IgG (black). 
The antibody is located in overlapping regions of the circles if the KD of the formats are 
within 5-fold of each other. Antibodies that do not bind a particular antigen are located 




The ability to rapidly produce antibodies has been accelerated by the invention of 
in vitro display systems including phage, ribosome, and microbial display (72). As a 
result of the necessity to maintain a link between genotype and phenotype and the 
complexity of expressing full-length antibodies outside of mammalian cell culture, all of 
these systems have relied on the display of recombinant antibody fragments. However, 
our lab recently developed a system for the display and selection of full-length IgG 
antibodies from combinatorial libraries expressed in E. coli (106). As a result, it is now 
possible to display and select recombinant antigen binding sites expressed in a variety of 
different formats. The present study sought to examine the limitations and relative merits 
of using different antibody formats in library screening experiments. 
 The diversity of antibody binding sites obtained when the same library of VH and 
VL domains from an immunized animal is screened as either IgG or scFv molecules is 
compared. The two libraries were screened by E. coli anchored periplasmic expression 
(APEx) using similar cell labeling and fluorescence activated cell sorting (FACS) 
conditions. A total of seven different antibodies specific for the protective antigen 
component of B. anthracis were isolated and were comprised of four different VH and 
four different VL germlines genes. IgG display accounted for 6 of these germlines which 
exhibited a wide range of (monovalent) affinities, although, a biding site with a slightly 
higher affinity (KD=6 nM) was isolated from the scFv library.  
Each pair of antibody variable domains comprising the seven anti-PA was  
expressed as scFv in two different orientations (VH-VL and VL-VH) as well as IgG 
molecules. Protein expression levels in E. coli and binding activity were evaluated. To 
maximize the expression and stability properties of the scFvs, they were expressed as 
scAbs since the addition of the human kappa constant is known to enhance these 
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properties of scFvs (62, 105). This analysis revealed that not only can converting the 
variable domains between the IgG and antibody fragment format adversely affect 
expression and antigen binding, but so can the orientation of the variable domains within 
an antibody fragment. Although scFvs are often unstable and can have reduced affinities 
compared to their Fab and IgG counterparts (52, 62, 105), the orientation of the variable 
domains compared to the linker is an approach to retain affinity upon conversion to the 
scFv, or in this case, the more stable scAb format. 
It was surprising that screening two different immune libraries generated from 
identical cDNA and each containing at least 107 members resulted in the isolation of 
different antibodies. Multiple attempts at screening the scFv library only resulted in the 
isolation of two different antibody clones. In contrast, a single attempt at screening the 
IgG library resulted in five unique antibodies. One possible explanation for the lower 
success rate of the scFv library screen is the inability of many variable domains to be 
expressed and maintain affinity in this format. It was shown that several pairs of variable 
domains isolated as IgGs displayed substantially reduced affinity when expressed as 
scAbs, and hence they were not recovered from the scFv library. Additionally, the 
variable domains from one of the two isolated scFvs did not express or function as an 
IgG, 
Our results indicate that the antibody format used during in vitro selection effects 
which antibody variable domains will be isolated during screening. In general, the full-
length IgG antibody was the preferred variable domain format to isolate antibodies from 
immune libraries expressed in E. coli. This is likely the result of the increased stability of 
the IgG compared to linker linked antibody fragments (52, 106). However, antibodies can 
also be isolated that only express and function as an antibody fragment and the 
orientation of the fragment can drastically impact both expression and binding properties. 
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Based on the unpredictable variation of antibody properties following variable domain 
format conversion, it is recommended to choose a library format based on the final 
application of the antibody. If effector function will be required as is typical with most 
cancer therapeutics, formats that best represent the IgG structure (i.e. Fab, Fab2, IgG) 
should be utilized during the discovery process. If enhanced biodistribution and blood 
clearance properties are required as is for imaging applications, smaller formats should be 
used (i.e. VH, VL, scFv). 
 
MATERIALS AND METHODS 
Bacterial strains and plasmid vectors 
Escherichia coli Jude-1 cells [DH10B F’::Tn10(Tetr)] were used for all 
experiments. Plasmids pAPEx1 was used for E. coli display of soluble single chain 
variable fragment antibodies (scFv) (59). Plasmids pMoPac16 and pMAZ360-IgG were 
used for soluble single chain antibody fragment (scAb) expression and IgG expression, 
respectively (106).  
 
Antibody fragment library construction 
Mice immunization with the protective antigen (PA83) component from Bacillus 
anthracis in complete Freud’s adjuvant and the isolation of VH and VL genes were 
performed using established procedures (106). The VH and VL genes were fused by 
overlap extension PCR to give rise to either VL-(Gly4Ser)4-VH scFv (VL-VH) according to 
published protocols or to VH-(Gly4Ser)4-VL scFv (VH-VL). The individual scFv gene 
pools, VH-VL and VL-VH, were separately cloned into pAPEx1 via the non-compatible 
SfiI sites, and the ligation products were transformed into electrocompetent E. coli Jude-1 
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(59). Cells were cultured on agar plates containing LB medium supplemented with 2% 
(wt/vol) glucose (2% glc) and 30 μg/ml chloramphenicol (Cm30) and grown overnight at 
25 ºC. Frozen cell stocks were prepared by transferring the cells to LB medium 
supplemented with 2% glc and 15% glycerol to A600 ~10 then stored at -80 ºC. 
 
Isolation of anti-PA antibodies  
Purified PA83, kindly provided by Stephen Leppla (National Institute of Health, 
Bethesda, MD), was conjugated to BODIPY® using 6-((4,4-difluoro-5,7-dimethyl-4-
bora-3a,4a-diaza-s-indacene-3-propionyl)amino)hexanoic acid succinimidyl ester 
(Invitrogen, Carlsbad, CA) at a molar ratio of 1:8 following the manufacturer’s protocol. 
Free BODIPY FL-X SE was removed using a NAP-10 gel filtration column following the 
manufacturer’s protocol (GE Healthcare, Uppsala, Sweden). The extent of conjugation 
was determined based on the ratio of A280 and A504 measured using a NanoDropTM 1000 
and the appropriate extinction coefficients and correction factors as recommended by the 
manufacturer (Invitrogen, Carlsbad, CA). PA83 extinction coefficient was calculated 
using Protein Calculator (http://www.scripps.edu/~cdputnam/protcalc.html, Putnam Lab at 
The Scripps Research Institute, La Jolla, CA).  
The VH-VL and VL-VH scFv library frozen cell stocks were thawed on ice, 
combined in proportion to the number of individual transformants, subcultured to A600 
0.1 in TB medium supplemented with 2% glc and Cm30, grown to A600 ~0.8-1.2 at 37ºC, 
cooled for 30 min to 25 ºC, and protein expression was induced with the addition of 1mM 
Isopropyl-β-d-thiogalactopyranoside (IPTG). After 4h induction at 25 ºC, 1 ml of cells at 
A600 8.0 were converted to spheroplasts using Tris/Sucrose/EDTA/lysozyme as described 
(59, 107). The spheroplasted cells were labeled with 200 nM PA63-FITC (List Biological 
Laboratories, Campbell, CA) in phosphate buffered saline (PBS) for 1 h at 25 ºC. Labeled 
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spheroplasts were washed with PBS and analyzed on a MoFlo (Dako, Glostrup, 
Denmark) droplet deflection flow cytometer by exciting with a 488-nm laser and 
measuring the fluorescence emission spectrum of FITC with a 530/40 band-pass filter. 
The library population was gated on the spheroplast population as determined by the 
forward scatter (FSC) and side scatter (SSC) parameters (106), and the most fluorescent 
1-2% of the population based on the FITC emission spectra was collected (59, 106). The 
collected spheroplasts were immediately resorted, and the scFv genes in the resort 
solution were by amplified by PCR using primers BRH06 (5’-
GCGGATAACAATTTCACACAGG-3’) and AHX89 (5’-
CGCAGTAGCGGTAAACGGC-3’) (59). The amplified DNA was cloned into pAPEx1 
via the non-compatible SfiI restriction sites, and the ligation mixture was transformed 
into electrocompetent E. coli Jude-1. At least 10-fold excess of colonies relative to the 
number of events in the resort were obtained. Colonies were scraped from the agar plates 
into liquid media and subjected to additional rounds of sorting as follows: (i) four 
additional rounds using decreasing concentrations of PA63-FITC down to 40 nM; (ii) one 
additional round using 400 nM PA83-BODIPY.  
The scFv genes from each round of sorting were subcloned into pMoPac16, and 
the ligation products were transformed into E. coli Jude-1 for expression of soluble scAb 
proteins (59). Briefly, approximately 200 individual colonies from both final rounds were 
picked and cultured at 30 ºC in round bottom 96-well microtiter plates containing 200 μl 
of TB medium supplemented with 2% glc and 200 μg/ml ampicillin (Amp200). After 
overnight growth, 4 μl aliquots were transferred to a master microtiter plate containing 
156 μl TB medium supplemented with 2% glc and Amp200, cultured for 8 h at 30 ºC, 
and stored at 4 ºC for up to two weeks. The remaining cells were pelleted by 
centrifugation and resuspended in 200 μl of TB medium supplemented with Amp200 and 
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1 mM IPTG to induce protein expression. After 4 h of incubation at 25 ºC, cells were 
pelleted by centrifugation and lysed by either sonication in 200 μl PBS or by incubation 
in 200 μl lysis buffer (BugBusterTM HT Protein Extraction Reagent (Novagen, Madison, 
WI) diluted 1:4 in PBS) (107) for 30 min at 25 ºC, and finally, the insoluble fractions 
were removed by centrifugation. Clarified lysates were individually analyzed for binding 
toward PA83 using enzyme-linked immunosorbent assay (ELISA) as described (106, 
107). ScAb immunocomplexes were detected using an anti-polyhistidine (anti-His) 
peroxidase (HRP) conjugate (Sigma-Aldrich, St. Louis, MO) applied at a 1:2,500. The 
screening of the VH and VL gene pool in the IgG format has been describe (106). 
Antibody variable domain germlines were determined using IGBlast 
(http://www.ncbi.nlm.nih.gov/igblast/, National Center for Biotechnology Information, 
Bethesda, MD). 
 
Variable domain format conversion 
The isolated scFv (B12, C9) and full-length anti-PA antibody (B2, C3, D1, F10, 
H2) variable domain genes were converted to VH-VL, VL-VH, and IgG formats. Briefly, 
genes encoding the variable domains in pMoPac16 and pMAZ360-IgG plasmid DNA 
were amplified by PCR using variable domain specific primers, combined by overlap 
extension PCR, and cloned into pMoPac16 via the non-compatible Sfi sites, Likewise, 
genes encoding variable domains in pMoPac16 were amplified by PCR and sequentially 
cloned into pMAZ360-IgG via NheI/HindIII and NcoI/NotI restriction sites. 
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Protein expression and purification 
Monomeric scAb and full-length IgG proteins were expressed and purified 
according to published procedures (59, 64, 106, 107). For scAb protein expression, E. 
coli Jude-1 containing pMoPac16 derivatives encoding the desired scAb genes were 
cultured in 2 ml of TB medium supplemented with 2% glc and Amp200 for 8 h at 30 ºC 
then used to inoculate of 500 ml of TB supplemented with 2% glc and Amp200. After 
overnight growth at 30 ºC, cells were pelleted by centrifugation and resuspended in 500 
ml of TB medium supplemented with Amp200 and 1 mM IPTG to induce protein 
expression. After 4 h of incubation at 25 ºC, cells were pelleted by centrifugation, and the 
periplasmic fraction from the cell pellet was isolated by osmotic shock according to 
published procedures (64). ScAb proteins were purified from the shockate by 
immobilized metal affinity chromatography (IMAC) using Ni-NTA Agarose based on the 
manufacturer’s protocol (Qiagen, Hilden, Germany), and monomeric scAbs were further 
isolated by size-exclusion FPLC (SEC) on a SuperdexTM 200 column (GE Healthcare, 
Uppsala, Sweden) using PBS or HBS-P (GE Healthcare, Uppsala, Sweden) as the elution 
buffer.  
For IgG protein expression, E. coli Jude-1 containing pMAZ360-IgG derivatives 
encoding the desired IgG genes were cultured in 10 ml of LB medium supplemented with 
2% glc and Amp200 overnight at 30 ºC. Overnight cultures were subcultured to A600 0.2 
in 500 ml of TB medium supplemented with 2% glc and Amp100, grown to A600 ~0.8-1.2 
at 30 ºC, cells were pelleted by centrifugation and resuspended in 500 ml of TB medium 
supplemented with Amp100 and 1 mM IPTG to induce protein expression. After 16 h of 
incubation at 25 ºC, cells were pelleted by centrifugation, resupsended in 50 ml lysis 
buffer for 2 h at 25 ºC, and the insoluble fraction was removed by centrifugation. IgG 
proteins were purified from the clarified lysate by Protein A chromatography (Pierce, 
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Rockford, IL) according to published procedures (107). IgG proteins were concentrated 
on an Amicon® Ultra 10K MWCO (Millipore, Billerica, MA) according to the 
manufacturer’s protocol using PBS or HBS-EP buffer. All proteins were quantified based 
on the A280 measured using a NanoDropTM 1000. Purity was determined by SDS-PAGE 
using either a 4-20% or 12% gel (NuSep, Lawrenceville, GA) stained with GelCode Blue 
(Thermo Fisher Scientific, Rockford, IL) for scAb and IgG proteins, respectively. All 
antibodies used in this work were at least 80% pure. 
 
Western blot analysis 
The scAb and IgG proteins were expressed essentially as described above. For 
scAb protein expression, 1 ml of TB medium supplemented with 2% glc and Amp200 
was inoculated with individual colonies of E. coli Jude-1 containing pMoPac16 
derivatives encoding the desired scAb genes and grown at 30 ºC. Overnight cultures were 
subcultured 1:20 in 1 ml of TB medium supplemented with 2% glc and Amp200 for 2 h 
at 30 °C, cells were pelleted by centrifugation and resuspended in TB medium 
supplemented with Amp200 and 1 mM IPTG to induce protein expression. After 4 h of 
incubation at 25ºC, total protein from an equivalent amount of cells based on A600 were 
resolved under reducing conditions by SDS-PAGE on a 4-20% gel and analyzed by 
Western blot with a 1:10,000 dilution of anti-His HRP conjugate as described (131).  
For full-length IgG protein expression, 1 ml of LB medium supplemented with 
2% glc and Amp100 was inoculated with individual colonies of E. coli Jude-1 containing 
pMAZ360-IgG derivatives encoding the desired IgG genes and grown at 30 ºC. 
Overnight cultures were subculture to 1:20 in 1 ml of TB medium supplemented with 2% 
glc and Amp100, grown to A600 ~0.8-1.2 at 30 ºC, cells were pelleted by centrifugation 
and resuspended in 1 ml of TB medium supplemented with Amp100 and 1 mM IPTG to 
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induce protein expression. After 16 h of incubation at 25ºC, total protein from an 
equivalent amount of cells based on A600 were resolved under non-reducing conditions by 
SDS-PAGE on a 12% gel and analyzed by Western blot with a 1:7,500 dilution of goat 
anti-human heavy and light chain IgG (anti-IgG) polyclonal serum peroxidase (HRP) 
conjugate (Jackson ImmunoResearch Laboratories, West Grove, PA) as described (106).   
 
Surface Plasmon resonance (SPR) 
The antigen binding kinetics of purified monomeric scAbs were determined as 
described (59). Briefly, approximately 400 response units (RU) of PA83 or PA63 were 
coupled to a CM5 chip (GE Healthcare, Uppsala, Sweden) by using 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide/N-hydroxy succinimide (EDC/NHS) chemistry. 
BSA was similarly coupled to the chip and used for in-line subtraction. Samples were 
injected for 1 min and dissociation was monitored for 5 min at 100 μl/min in HBS-P. The 
surface was regenerated with a pulse of 4 M MgCl2. Several 2-fold dilutions of each 
antibody beginning at an appropriate concentration were performed in duplicate, double 
referenced with a blank, and kon and koff determined using BIAevaluation software (GE 
Healthcare, Uppsala, Sweden) (115).  
The antigen binding kinetics of purified IgGs were determined as described (106). 
Briefly, approximately 10,000 RU of goat anti-human IgG1 Fcγ fragment specific (anti-
Fc) (Jackson ImmunoResearch Laboratories, West Grove, PA) were coupled to a CM5 
chip by using EDC/NHS chemistry. ~3 μg/ml of purified IgG in HBS-P was injected at 5 
μl/min to achieve ~100 RU of captured IgG, stabilized with buffer for 5 min at 50 μl/min, 
and PA83 or PA63 was injected for 1 min and dissociation monitored for 5 min at 50 
μl/min. The surface was regenerated with a pulse of 100 mM H3PO4. Several 2-fold 
dilutions of PA83 or PA63 beginning at 200 nM were performed in duplicate, double 
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referenced with a blank, and kon and koff were determined using BIAevaluation software 
(115). The antigen binding kinetics of purified IgG were also determined by directing 
binding as described above for monomeric scAbs. 
 
ELISA 
Apparent antibody affinity (KD) was determined by ELISA half-maximal binding. 
Briefly, Costar® high binding 96-well EIA/RIA plates were coated overnight at 4º C with 
50 μl of 5 μg/ml PA83, PA63, or transferrin in PBS. The plates were washed with PBS 
then blocked with PBS supplemented with 2% milk (MPBS). Ten 2-fold dilutions of 
purified monomeric antibody (either scAb or IgG) in MPBS were performed in duplicate 
starting at up to 4 μM in concentration and incubated at room temperature for 2 h. The 
plates were washed with PBS and PBST. ScAb immunocomplexes were detected as 
described above. IgG immunocomplexes were detected using an anti-IgG HRP conjugate 
as described (106, 107). The plates were washed, developed, and the A450 was measured. 
The A450 for duplicate runs was averaged, and the specific A450 (Aspecific) for each 
antibody concentration was determined by subtracting the background. An apparent KD 
for each antibody toward either PA83 or PA63 was determined from the plot of Aspecific as a 
function of antibody concentration ([Ab]) using a modified version of the non-linear 
optimization approach described (26). The Solver tool in Microsoft ExcelTM (Microsoft, 
Redmond, WA) was used to calculate the KD by varying KD, Arange, and Amin to minimize 
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Optimization of Library Screening by APEx 
 
INTRODUCTION 
Anchored periplasmic expression (APEx) is a protein display technology that has 
been used successfully for antibody engineering in vitro (59). In APEx, antibody 
fragments are anchored onto the periplasmic side of the inner membrane via fusion to 
either a transmembrane domain of an integral membrane protein or to the signal peptide 
and the first few N-terminal amino acids of an inner membrane lipoprotein, such as NlpA 
(59, 79). The latter anchoring strategy is usually preferable because lipoprotein fusions 
can be expressed at higher levels. For the detection and subsequent isolation of antigen 
specific antibody fragments, the cells are converted to spheroplasts in order to disrupt the 
outer membrane and peptidoglycan layer, incubated with a fluorescently labeled antigen, 
and isolated by fluorescence activated cell sorting (FACS) based on high fluorescence. 
APEx was effectively used to increase the affinities of two single chain variable fragment 
antibodies derived from hybridomas. The affinity of one of these antibodies was 
increased from 4300 to 35 pM, and this increase was essential for therapeutic potency in 
animal models of the disease (98, 105). Additionally, APEx was used to increase the 
affinity of two other antibodies by at least 100-fold giving rise to scFvs exhibiting 
equilibrium dissociation constants in the range of 45-100 pM (Chapter 2 and M. Rani, 
T.V.B., G.G., and B.I. unpublished data).  
In this work, I used APEx for the screening of mouse immune libraries. Three 
antigens were used to immunize mice: the protective antigen (PA) from Bacillus 
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anthracis, human soluble tumor necrosis factor receptor I (TNF-RI), and human soluble 
tumor necrosis factor receptor II (TNF-RII). The serum titers from the respective mice 
indicated a significant immune response to these antigens. The VH and VL genes were 
amplified by RT-PCR from splenocytes and scFv combinatorial libraries were displayed 
using APEx. However, following several rounds of sorting, only two antibodies for the 
Bacillus anthracis protective antigen (PA) and none for either TNF-RI or TNF-RII were 
isolated (Chapter 2; data not shown).  
The limited success of these studies contrasts the very successful application of 
APEx for antibody affinity maturation discussed above. Here I undertook extensive 
studies to optimize the efficiency of library screening by APEx. One of the issues 
encountered during the screening of immune libraries was the selection of the correct 
population of spheroplasts to be collected by the flow cytometer during FACS. In flow 
cytometry, the forward and side scatter (FSC and SSC respectively) of the laser beam are 
roughly proportional to the relative size and internal complexity of individual cells in a 
population. The FSC and SSC signals of a population of intact E. coli normally have a 
narrow distribution. However, following spheroplasting, i.e. the chemical removal of the 
cell’s outer membrane and cell wall, the FSC and SSC signals become more complex. 
Thus distinguishing the cells to be interrogated for their fluorescence properties becomes 
more difficult. In the immune library screens mentioned above, simultaneous labeling for 
both antigen binding and inner membrane integrity, which has been shown to increase the 
isolation efficiency of antigen specific antibodies, was also an ineffective approach (38, 
59). Further, antibodies from immune libraries will have lower affinities compared to 
antibodies isolated during affinity maturation. Lower affinity leads to cells with lower 
fluorescence which is more difficult to distinguish from cells displaying antibodies 
without the desired antigen specificity.  
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In this chapter I introduced several modifications to the APEx methodology: First, 
the APEx expression system was reengineered by incorporating a C-terminal epitope 
peptide that allows for the detection of the absolute amount of antibody protein displayed 
on a cell. In this manner both the amount of protein and antigen binding can be 
determined simultaneously by 2-color flow cytometry. Second, this system was used 
examine the effects of converting E. coli to spheroplasts and led to the development of 
optimal FACS settings. The combination of simultaneous detection of antibody 
expression levels and binding coupled with optimized FACS settings was shown to 
enable the isolation of antigen specific antibodies in a more efficient manner. Third, 
additional strategies for protein display in E. coli were discovered (106). Specifically, 
soluble proteins expressed in the periplasm of E. coli were found to be retained following 
conversion to spherplasts. The degree to which soluble proteins were retained by 
spheroplasts was roughly proportional to their molecular weight. The lack of an 
anchoring motif resulted in a slight decrease in fluorescence, but nonetheless the cell 




The chemical and enzymatic treatment used to create E. coli spheroplasts results 
in a more heterogeneous population compared to untreated cells. These morphological 
differences in turn result in an altered FSC and SSC signals relative to untreated E. coli 
cells (Figure 3.1). Spheroplasted cells expressing the 26.10 scFv with and without a C- 
 
        
E. Coli              
After
E. Coli                             
Before
 
Figure 3.1. Comparison of.E. coli and E. coli spheroplasts by flow cytometry.   
FSC vs. SSC signals of an E. coli population before and after treatment with Tris-
Sucrose, EDTA, Lysozyme, and MgCl2. 
terminal FLAG epitope FLAG epitope peptide were fluorescently labeled with anti-
FLAG-PE (59). The fluorescence emission intensity of fluorescently labeled spheroplasts 
shows a broad distribution as determined by flow cytometry (Figure 3.2). The fluorescent 
signal of both the control cells and the cells expressing an antibody fused with a C-
terminal FLAG peptide increased with cell size as determined by the FSC and SSC 
signals. The increase of the fluorescence signal with cell size was more pronounced for 
cells expressing the scFv-FLAG fusion.    
Spheroplasts expressing scFv either with or without the FLAG peptide and 
labeled with anti-FLAG-PE were imaged using an inverted fluorescence microscope 
under brightfield and fluorescence emission (Figure 3.3). Brightfield microscopy 
confirmed that the spheroplast treatment resulted in the convertion of more than 90% of 
the E. coli into spherical cells, as a result of the degradation of the cell wall and the 
solubilization of the outer membrane (14). In addition, however, large aggregates 
comprising of many tens of spheroplasted cells were also observed. Following labeling 













Figure 3.2.  Flow cytometry gating effects on fluorescent signals. 
Two monoclonal populations of spheroplasts displaying a scFv either with or without a 
C-terminal FLAG epitope peptide using APEx were fluorescently labeled with 5 mg/ml 
anti-FLAG-PE. Each population was analyzed by flow cytometry based on FSC, SSC, 
and PE emission signals. (A) Three gates were created based on FSC vs. SSC signal. (B) 
The PE emission distribution of each monoclonal population based on the gates in (A) are 
depicted on separate histograms.  The geometric mean (GM) of the gated population is 
indicated. , FLAG(-), scFv without FLAG peptide; , FLAG(+), scFv with FLAG peptide. 
FLAG-PE), only spheroplasts expressing scFv-FLAG became fluorescent (Figure 3.3). 
The intensity of the fluorescence emission correlated with the size of the cell aggregates. 
High fluorescent aggregates represent an artifact in sorting experiment because the 
fluorescence intensity does not arise from better binding of the label on a per cell basis 
but instead it is the consequence of the large number of ligands in the aggregate. In other 
words the aggregates fluoresce intensely even if their constituent cells express proteins 
that bind weakly to the probe. As a result, the isolation of highly fluorescent events 
comprised of aggregates fails to give rise to useful antibodies. Note that in the field of 
view shown in Figure 3.3 labeled FLAG(+), one spheroplast was found not to be 
fluorescent and was highlighted in white. Such non-fluorescent cells can arise either from 
the loss of the plasmid that encodes the scFv-FLAG protein or from incomplete 
disruption of the cell wall and outer membrane which in turn could prevent the binding of 
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Figure 3.3.  Microscopy images correlate “spheroplast” size and fluorescence. 
Two monoclonal populations of spheroplasts displaying a scFv either with or without a 
C-terminal FLAG epitope peptide using APEx were fluorescently labeled with 5 mg/ml 
anti-FLAG-PE and imaged under visible light and with fluorescence emission (>590 nm).  
Red circles indicate fluorescent objects and white circles indicate non-fluorescent 
“spheroplasts”. The three “spheroplasts” labeled 1, 2, and 3 were digital magnified to the 
same degree. FLAG(-), scFv without FLAG peptide; FLAG(+), scFv with FLAG peptide. 
 
Optimized Gates for FACS 
A FACS enrichment experiment was designed to determine the optimum FSC and 
SSC signals that enable the recovery of individual spheroplasts displaying antibodies 
with desired binding properties as determined by fluorescence emission. The ability to 
isolate spheroplasts displaying a single domain antibody (dAb) from spheroplasts 
displaying a scFv with different binding specificities was easily determined by PCR 
analysis of the population isolated by FACS since the size of the genes encoding these 
antibodies are different. A gene encoding a TNF-RI specific dAb fused to a C-terminal 
FLAG peptide was constructed. The dAb gene was also fused to the leader peptide and 
first 6 amino acids of NlpA for display on the inner membrane of E. coli. Cells 
expressing this molecules were designated dAb(+). dAb(+) cells were converted to 
spheroplasts and mixed with control spheroplasts displaying an unrelated antibody, 
namely the anti-digoxigenin 26.10 scFv either with or without a C-terminal FLAG 
peptide (scFv(+) and scFv(-), respectively). 1:1 mixtures of dAb(+) with scFv(-) or 
scFv(+) and also unmixed dAb(+), scFv(-), and scFv (+) spheroplasts were labeled with 
TNF-RI expressed andpurified from insect cells and conjugated to the fluorescent dye 



















Figure 3.4.  Optimized FACS gate for APEx. 
FSC vs. SSC flow cytometry signal of E. coli spheroplasts. The New gate for FACS is 
depicted. Spheroplasts displaying various antibody fragments using APEx were 
fluorescently labeled with 5 μg/ml anti-FLAG-PE and 2.5 μM TNF-RI-BODIPY and the 
fluorescence emission distribution of PE (Expression Level) and BODIPY (Antigen 
Binding) for the total population (top row) or gated population (bottom row) are shown. 
scFv(-), anti-digoxigenin scFv; scFv(+), anti-digoxigenin scFv with C-terminal FLAG 
peptide; dAb(+) anti-TNF-RI dAb with C-terminal FLAG peptide. 
The FSC vs. SSC dot plot data were gated to either account for the total cell population 
(total) or to exclude the large intensely fluorescent aggregates, which as described above 
are undesirable for library screening purposes. The latter gate that excludes aggregates 
was termed “New gate” in Figure 3.4. The dAb(+):scFv(-) and dAb(+):scFv(+) mixtures 
 75
 76
were sorted either by using the total or the New gate settings and events displaying high 
PE and BODIPY fluorescence were collected (Figure 3.5). Analysis of the resulting 
population revealed that the fraction of the desired dAb(+) clones after sorting of the 
dAb(+):scFv(-) mixture was increased from 50% to 90% using the “new gate” compared 
to 70% using the “total” gate. Similarly, after sorting of the dAb(+):scFv(+) mixture the 
“New gate” resulted in 80% dAb(+) clones compared to 60% without.  
 
Retention of Higher Molecular Weight Antibodies by Spheroplasts 
In the studies described so far in this work, libraries of IgG antibodies or antibody 
fragments had been tethered onto the E. coli inner membrane to prevent their release 
from spheroplasts after the outer membrane had been disrupted. It was noticed, however, 
that in many instances, cells expressing antibody fragments in a soluble form within the 
periplasmic space could also be stained by fluorescent ligands following spheroplasting. 
These observations indicated that under certain conditions soluble periplasmic proteins 
are retained by spheroplasts via an unknown mechanism. Experiments were carried out to 
investigate whether the retention of  
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Figure 3.5.  FACS enrichment experiment. 
Equally mixed populations of spheroplasts displaying different antibody fragments using 
APEx were fluorescently labeled with 5 μg/ml anti-FLAG-PE and 2.5 μM TNF-RI-
BODIPY. (A) The fluorescence emission distribution of PE (Expression Level) and 
BODIPY (Antigen Binding) for the total population (total) or gated population (New 
gate) of each sample are shown. (B) PCR recovery of antibody genes following one 
round of FACS. The brightest events in terms of PE and BODIPY fluorescence emission 
from the total or New gate FSC vs. SSC population were collected using the depicted 
gate in order to isolate the anti-TNF-RI dAb. The antibody genes from the collected 
spheroplasts were amplified by PCR using identical primers, separated on an agarose gel, 
imaged under UV light, and the PCR product percentages were determined using 
densitometry analysis. scFv(-), anti-digoxigenin scFv; scFv(+), anti-digoxigenin scFv 
with C-terminal FLAG peptide; dAb(+) anti-TNF-RI dAb with C-terminal FLAG 
peptide. 
soluble periplasmic ligand binding proteins following spheroplasting is dependent on the 
molecular weight of the polypeptide. Plasmids were constructed for E. coli periplasmic 
expression of the anti-PA antibody M18.1 in different recombinant antibody formats 
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having varying molecular weights (Table 3.1 and 3.2). Additionally, plasmids were 
constructed for scFv and IgG anchoring to the periplasmic face of the inner membrane. 
scFv anchoring was accomplished by creating either N- or C-terminal fusions to the E. 
coli new lipoprotein A (NlpA) or to the M13 bacteriophage gene III protein (g3p), 
respectively (59). IgG anchoring was accomplished by non-covalent binding to an NlpA-
ZZ domain fusion (106). The ZZ domain is a synthetic analogue of the IgG binding 
domain of Staphylococcus aureus Protein A. The inner membrane tethered NlpA-ZZ non-
covalently captures the solubly expressed IgG antibody which becomes associated with 
the inner membrane. In this system, the IgG is expressed under control of the lac 
promoter whereas the NlpA-ZZ is expressed under control of the arabinose-dependent 
BAD promoter (106). Cells were converted to spheroplasts, fluorescently labeled with  
 
Table 3.1. Plasmids used in this study 
Plasmid Purpose Relevant characteristics Source 
pMoPac12 scFv expression Amp
r, lac promoter, pelB leader, skp 
gene (65) 
pMoPac16 scAb expression HuC gene in pMoPac12 (65) 
pAPEx1 scFv N-terminal anchoring Cm
r, lac promoter, NlpA leader and 
amino acids 1-6 (59) 
pFLAG-APEx scFv N-terminal anchoring  & C-terminal FLAG C-terminal FLAG peptide in pAPEx1 
This 
study 
pAK200 scFv C-terminal anchoring Cm
r, lac promoter, truncated gene III 
protein (g3p)amino acids 250-406 (87) 
pMAZ360-IgG IgG expression Ampr, lac promoter, pelB leaders (106) 
pBAD33-NlpA-ZZ ZZ domain N-terminal anchoring Cm
r, BAD promoter, NlpA leader  
and amino acids 1-6 (106) 
 
Table 3.2. Molecular weights of recombinant antibody formats 




PA-FITC, and analyzed by flow cytometry. Spheroplasts containing the anti-digoxigenin 
26.10 scFv as an NlpA fusion were used as a negative control for antigen binding. Cells 
expressing any of the anti-PA antibody fragments in a soluble form, including the smaller 
scFv exhibited at least 3-fold higher fluorescence compared the control as determined by 
the geometric means of the populations (Figure 3.6). The N-terminal scFv fusion (NlpA-
scFv) resulted in a more uniform and enhanced fluorescence distribution compared to the 
C-terminal fusion (scFv-g3p), which is consistent with previous accounts (59). The 
highest fluorescence was obtained for NlpA-scFv and anchored IgG (IgG + NlpA-ZZ). 
IgG expression without the anchoring ZZ domain resulted in a 60% fluorescence 
reduction, which was nonetheless still 10-fold higher than that of the control. Soluble 
scFv expression resulted in a 7-fold lower fluorescence relative to the NlpA anchored 
version. Expression of the larger scAb fragment (45 kDa vs 30 Kda for scFvs) resulted in 
a 2-fold lower fluorescence relative to the NlpA anchored scFv.  
 
NlpA-scFv scFv-g3p NlpA-scFv IgG + NlpA-ZZ
scFv scAb IgG
GM 3 GM 10 GM 71 GM 79
GM 10 GM 35 GM 32
26.10 M18.1
 
Figure 3.6.  Effect of antibody molecular weight and anchoring approaches. 
Spheroplasts displaying antibodies with different antigen specificities, in different 
formats, with or without inner membrane anchoring were fluorescently labeled with 
PA63-FITC. The spheroplast populations were gated based on FSC vs. SSC and the 
resulting FITC fluorescence emission distribution and geometric mean (GM) are shown. 




In the standard APEx sorting protocol, the spheroplasts are fluorescently labeled 
for both antigen binding and inner membrane integrity (59). Monitoring inner membrane 
integrity with stains such as propidium iodide, a membrane impermeable molecule that 
only fluoresces when it intercalates with nucleic acids, has been shown to minimize the 
isolation of cells displaying antibodies that non-specifically bind to the fluorescently 
labeled antigen (38). This is accomplished by selecting cells based on high fluorescence 
emission for antigen binding and low emission for propidium iodide. However, when 
labeling antibodies displayed using APEx in this manner, the fluorescent signals for 
antigen binding and inner-membrane integrity increase relative to each other so the 
benefit of monitoring inner membrane integrity with APEx is questionable (59). 
The fusion of a C-terminal FLAG epitope peptide to antibody fragments enables 
the detection of antibody expression levels (17). Thus, antigen binding per antibody can 
be normalized and cells displaying the highest affinity antibodies may be isolated by 
FACS. We showed that the incorporation of the FLAG peptide and labeling with anti-
FLAG-PE resulted in a highly fluorescent population as compared to a population 
without the FLAG peptide (Figure 3.2). As is typically seen when fluorescently labeling 
spheroplasts displaying antibodies using APEx, the fluorescence intensity of each 
population increased with increasing FSC vs. SSC signals. This correlation between 
fluorescence and size was analyzed by brightfield and fluorescence microscopy (Figure 
3.3). Although the majority of the population was individual spheroplasts that are 
approximately the same size as normal E. coli (data not shown), large aggregates were 
also observed. These aggregates were found to be highly fluorescent and their formation 
correlates with the highly fluorescent signals seen in dot plot regions of high FSC vs. 
SSC (Figure 3.2). In an antibody library there are very few cells displaying antigen 
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specific antibodies. By contrast, aggregates comprised of both intact and partially lysed 
spheroplasts display high non-specific labeling (data not shown). As a result, the sorting 
of fluorescent aggregates gives rise to clones that display low affinity or highly 
unspecific antibodies, while desired clones that exist as individual spheroplasts, and thus 
exhibit lower fluorescence, are overlooked. The design of an improved gating strategy 
restricting the FSC vs. SSC signals resulted in a higher enrichment efficiency of cells 
displaying antigen specific antibodies (Figure 3.5). This approach was used to isolate 
high affinity antibody variants specific for the V antigen of Yersinia pestis (Chapter 4). 
In most protein display technologies, the antibody is displayed by creating a 
fusion between the antibody and a protein on the surface of the biological particle, such 
as a cell or bacteriphage. Antibodies expressed in the context of a fusion partner can be 
more stable and express better compared to their expression as unfused molecules. For 
example, it has been observed that scFvs isolated as fusions using phage display do not 
function when expressed on their own (78). It is undesirable to isolate antibodies with 
this characteristic since the antibody will eventually need to be expressed as a soluble 
protein for practical applications. Further, it is difficult to display complex proteins that 
contain multiple polypeptides as fusions. For example, creating a fusion with either the 
full-length light or heavy chain of an antibody would likely inhibit all four chains to 
assembly into a functional IgG since two identical chains would be anchored by different 
proteins, thus a spatial separation would prevent their assembly. In this study, it was 
shown that 150 kDa full-length IgG antibodies expressed as soluble proteins in the 
periplasm of E. coli are retained by spheroplasts and can be detected by flow cytometry 
following specific labeling with fluorescently labeled antigen (Figure 3.6). Additional 
experiments with a ~30 kDa scFv and a ~45 kDa scAb antibody fragment also 
demonstrated that expression of these proteins in soluble form in the periplasm results in 
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specific labeling following conversion of E. coli to spheroplasts. This finding was 
surprising since the disruption of the bacterial outer membrane results in the release of 
the contents of the periplasm into the surrounding environment, a phenomenon that has 
been extensively documented for over 40 years and exploited for the purification of 
periplasmic proteins (66, 88). The mechanism that underlies this observation is not clear. 
Two possible explanations are: (i) a portion of the “solubly” expressed polypeptide is not 
processed by the signal peptidase and thus retains the signal peptide which is an N-
terminal hydrophobic sequence that directs export across the membrane. The signal 
sequence forms a transmembrane α-helix which then serves to anchor the polypeptide in 
the membrane. Such inhibition of signal peptide processing may be occurring because the 
antibody fragment is overexpressed and the large amount of protein may result in 
saturation of the signal peptidase. (ii) The antibody fragment is present in a fully soluble 
form in the periplasm but it is localized in a cell envelope compartment that is enmeshed 
in cell wall fragments. Such cell wall remnants have been observed in electron 
micrographs of spheroplasted cells (14). Regardless of the precise mechanism, the data 
presented here indicates that the retention of solubly expressed proteins by spheroplasts is 
dependent on the molecular weight.  
A significant advantage of this fusion-free antibody engineering approach 
compared to its predecessors is its compatibility with higher molecular weight antigens, 
which is typical of most therapeutic antibodies (24). A previously described fusion-free 
system referred to as periplasmic expression with cytometric screening (PECS) was 
successfully used to isolate and engineer antibody fragments with desired specificity. 
However, it was only compatible with antigens less than 10 kDa in size, which is 
relatively small for a protein (29) In this study, the antigen used is a 63 kDa protein and 
additional studies have demonstrated specific binding with antigens up to 150 kDa (data 
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not shown). Although this study did not include a library screening experiment, 
experimental evidence suggests that it is feasible. For example, even though spheroplasts 
expressing soluble antibody fragments having a lower molecular weight exhibit a more 
marked decrease in fluorescence signal relative to the corresponding anchored protein 
construct, the fluorescence signal is still several fold higher than controls, and thus 
sufficient for library screening experiments. Therefore, this fusion-free approach can be 
used to engineering a variety of binding proteins toward a wide range of antigens as long 
as the binding proteins can be functionally expressed in the periplasm of E. coli.  
 
MATERIALS AND METHODS 
Bacterial strains and plasmid vectors 
Escherichia coli Jude-1 [DH10B F’::Tn10(Tetr)] was used for all experiments. All 
plasmids used in this study are summarized in Table 3.1. Plasmid pMoPac12, pMoPac16, 
and pMAZ360-IgG were used for soluble single chain variable fragment (scFv), single 
chain antibody fragment (scAb), and full-length antibody (IgG) expression, respectively, 
and have been described (65, 106). Plasmid pBAD33-NlpA-ZZ was used to display an 
IgG binding domain (106). Plasmids pAPEx1 and pAK200 were used for N-terminal and 
C-terminal display of scFv, respectively (59). pFLAG-APEx was constructed by 
replacing the polyhistidine and c-myc sequences in pAPEx1 via BamHI and NotI 
restriction sites with the FLAG epitope peptide sequence amplified by PCR using primers 
TVB100 (5’-
GTCGCTGCGGCCGCAGATTACAAAGACGACGATGACAAGTAGTGATATCGCA
AGCTTGACC-3’) and TVB101 (5’-
CAGCGAGGATCCGTGACGCAGTAGCGGTAAACGGC-3’). A single domain 
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antibody (dAb) specific for TNF-RI (TAR2H-10 Sequence ID No. 31; Domantis, 
Cambridge, UK) was assembled by PCR according to established protocols (74). The 
dAb was cloned into pFLAG-APEx via the non-compatible SfiI restriction sites, and the 
ligation product was transformed into chemically competent E. coli Jude-1. 
 
Fluorescence Microscopy 
The anti-digoxigenin 26.10 scFv gene (59) was cloned into pAPEx1 and pFLAG-
APEx via the non-compatible SfiI restriction sites, and the ligation products were 
transformed into chemically competent E. coli Jude-1 cells. Cells were cultured at 30 ºC 
in 2 ml of Terrific Broth (TB) medium (Becton Dickinson Difco™, Sparks, MD) 
supplemented with 2% (w/v) glucose (2% glc) and 30 g/ml chloramphenicol (Cm30). 
After overnight growth, cells were subcultured to A600 0.1 in 2 ml TB medium 
supplemented with 2% glc and Cm30 at 37 ºC, grown to A600 ~0.8-1.2, cooled for 30 
min to 25 ºC, and protein expression was induced with the addition of 1mM IPTG. After 
4h of incubation at 25 ºC, 1 ml of cells at A600=8.0 were converted to spheroplasts using 
Tris/Sucrose/EDTA/lysozyme as previously described (59, 107). The spheroplasted cells 
were labeled with 5 g/ml PhycoLink® anti-Flag® R-Phycoerythrin (anti-Flag PE) 
(Prozyme, San Leandro, CA) in PBS for 30 min at 25 ºC, then washed with PBS. 
Spheroplasts were imaged with a Leica DM IRBE inverted fluorescence microscope 
(Leica Microsystems, Wetzlar, Germany) equipped with a Leica DFC350 FX 
fluorescence camera.  
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Fluorescence Activated Cell Sorting 
Tumor necrosis factor receptor I (TNF-RI) kindly provided by M. Rani (The 
University of Texas at Austin) was conjugated to BODIPYTM using 6-((4,4-difluoro-5,7-
dimethyl-4-bora-3a,4a-diaza-s-indacene-3-propionyl)amino)hexanoic acid succinimidyl 
ester (Invitrogen, Carlsbad, CA) at a molar ratio of 1:10 following the manufacturer’s 
protocol. Free BODIPY FL-X SE was removed using a NAP-10 gel filtration column 
following the manufacturer’s protocol (GE Healthcare, Uppsala, Sweden). The extent of 
conjugation was determined based on the ratio of A280 and A504 measured using a 
NanoDropTM 1000 and the appropriate extinction coefficients and correction factors as 
recommended by the manufacturer (Invitrogen, Carlsbad, CA; 
http://www.scripps.edu/~cdputnam/protcalc.html, Putnam Lab at The Scripps Research 
Institute, La Jolla, CA). E. coli Jude-1 containing pAPEx1 encoding 26.10 scFv (scFv(-)), 
pFLAG-APEx encoding 26.10 scFv (scFv(+)), and pFLAG-APEx encoding the dAb 
(dAb(+)) were grown, protein expression induced, and converted to spheroplasts as 
described above. An equal number scFv(-) and dAb(+) spheroplasts were combined as 
were scFv(+) and dAb(+) spheroplasts. All the combined and individual spheroplast 
populations were fluorescently labeled for antigen binding and antibody expression 
levels. Briefly, spheroplasted cells were first labeled with 5 g/ml PhycoLink® anti-
Flag® R-Phycoerythrin (anti-Flag PE) (Prozyme, San Leandro, CA) in PBS for 30 min at 
25 ºC. The spheroplasts were washed with PBS, labeled with 2.5 M TNF-RI conjugated 
to BODIPY (RI-BODIPY) in PBS for 1 h at 25 ºC. The spheroplasts were washed with 
PBS and analyzed on a MoFlo (Dako, Glostrup, Denmark) droplet deflection flow 
cytometer by exciting with a 488-nm laser and measuring the fluorescence emission 
spectrum of BODIPY and PE with 530/40 and 570/40 band-pass filters, respectively. 
Fluorescence compensation was performed as previously described (107). The 
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spheroplast populations were gated by the forward scatter (FSC) and side scatter (SSC) 
parameters, and 7,000 of the most fluorescent events from the population based on both 
the BODIPY and PE emission spectra were collected as described under Results (59, 
107). The antibody genes (scFv or dAb) from the collected spheroplasts were by 
amplified by PCR using primers BRH06 (5’-GCGGATAACAATTTCACACAGG-3’) 
and AHX89 (5’-CGCAGTAGCGGTAAACGGC-3’) (59). The amplified DNA was 
analyzed on a 1% agarose gel under UV light. The band intensities were determined by 
densitometry analysis software. 
 
Flow Cytometry 
E. coli Jude-1 containing pMoPac12, pMoPac16, pAPEx1, and pAK200 plasmids 
encoding the anti-PA M18.1 scFv, and the plasmid pAPEx1 encoding 26.10 were 
individually cultured and converted to spheroplasts as described above. E. coli Jude-1 
containing pMAZ360-IgG encoding for M18.1 IgG and also with and without pBAD33-
NlpA-ZZ, were cultured in 2 ml of LB medium supplemented with 2% glc and Amp200 
(and Cm30 for with pBAD33-NlpA-ZZ) overnight at 30 ºC. The cells were diluted into 2 
ml of TB media supplemented with 2% glc, Amp100, and Cm30 to an A600 0.2, grown 
to A600 ~0.8-1.2 at 30 ºC, pelleted by centrifugation and resuspended in fresh media as 
above but also containing 1 mM IPTG to induce protein expression. After 16 h of 
incubation at 25 ºC, NlpA-ZZ protein expression was induced from pBAD33-NlpA-ZZ 
by the addition of 0.2% arabinose (w/v) and the cells were incubated for an additional 3 
hours at 25 ºC. Subsequently, the cells were converted to spheroplasts as described above 
and labeled with 200 nM PA63-FITC (List Biological Laboratories, Campbell, CA) in 
PBS for 1 h at 25 ºC. Labeled spheroplasts were washed with PBS and analyzed on a 
FACSCalibur (Becton Dickinson Biosciences, San Jose, CA) flow cytometer by exciting 
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with a 488-nm laser and measuring the fluorescence emission spectrum of FITC with a 





Affinity Maturation of an Anti-V Antigen IgG Expressed                           
In Situ Via Adenovirus Gene Delivery Confers Enhanced                   
Protection Against Yersinia pestis Challenge 
 
INTRODUCTION 
Yersinia pestis is the etiologic agent of the plague and has been responsible for 
pandemic outbreaks occurring throughout the course of history. Although advances in our 
current living conditions, public health practices, and antibiotic therapies make future 
pandemics unlikely, outbreaks of plague resulting from biological warfare are a real 
threat. The features of Y. pestis that make it an attractive option for use as a biological 
weapon include availability of the organism, capacity for aerosol dissemination, potential 
for spread of secondary cases, and the high fatality rate of the pneumonic form of plague. 
In endemic regions of the world, the bacterium survives by causing chronic disease in 
animal reservoirs. It is spread among these animals and occasionally to humans 
predominantly through a flea vector, such as Xenopsylla cheopis (21, 147). Without 
prompt antibiotic therapy, approximately 50% of bubonic plague infections are fatal and 
can progress to the more dangerous pneumonic plague (147). Respiratory droplets from a 
pneumonic infected individual promote rapid spread through a susceptible population. 
Symptoms develop in 1 to 6 days post-infection and the disease progresses rapidly from a 
flu-like illness to severe pneumonia with coughing, chest pain, and bloody sputum. To be 
effective, antibiotic therapy must be administered early. If treatment is delayed more than 
24 hours following the onset of symptoms, the fatality rate is extremely high (165). 
Additionally, the presence of antibiotic-resistant strains of Y. pestis renders antibiotic 
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therapy unreliable. Fro these reasons, Y. pestis is a likely agent to be used as a biological 
weapon since aerosolized bacteria can confer widespread pneumonic plague (147). 
Of the 11 Yersinia species, only Y. pestis, Y. enterocolitica, and Y. 
pseudotuberculosis are human pathogens. Y. pestis is a gram-negative, non-motile, non-
spore-forming bacterium that replicates intracellularly during the early stages of infection 
and grows predominantly extracellularly at later stages of the infectious cycle (147). At 
present, no plague vaccine has been approved for use in the US. Passive immunization 
with antibodies specific for the LcrV protein (V antigen) is an attractive alternative to 
vaccines and have been shown to be effective against lethal challenges with Y. pestis (67-
69, 149). The V antigen plays a central role in plague pathogenesis. It activates the type 
III secretion system and thus mediates translocation of effector proteins (Yops) into host 
macrophages. It is also released from the bacteria and has immunosuppressive functions 
manifested by increasing levels of the anti-inflammatory cytokine interleukin 10 and 
decreasing levels of TNF-α (147). A recently developed anti-V antigen monoclonal 
antibody (mAb) 2C14.4 has been shown to confer protection against lethal challenge with 
intranasally administered Y. pestis in a dose-dependent manner (149). 
For several neutralizing antibodies the degree of protection against challenge with 
pathogen correlates with antigen binding affinity (5, 101, 105, 162). For example, while 
monoclonal antibodies and antibody fragments to the Protective Antigen (PA) of Bacillus 
anthracis with a KD=11 nM fail to confer protection against challenge with the holotoxin 
or with intranasally administered spores, engineered antibody variants displaying 40- to 
200-fold higher affinities were protective in different animal models (98, 105). Notably, 
protection appeared to be mediated by blocking the ability of PA to bind to its receptor 
since PEGylated antibody fragments exhibiting a KD=35 pM but lacking an Fc domain, 
and hence incapable of engaging innate immunity mechanisms of pathogen clearance, 
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were protective (98). Engineering antibodies with high affinity has been shown to 
improve protection for other protein toxins and viruses including Botulism, human 
immunodeficiency virus (HIV), and human respiratory syncytial virus (RSV) and have 
increased efficacy when targeting inflammatory cytokines such as TNF-α (5, 101, 105, 
126, 131, 162). 
In this study, we evaluated whether Ad-mediated delivery of an engineered 
2C14.4 IgG exhibiting markedly increased affinity directed towards the V antigen can 
improve protection against Y. pestis challenge in mice (149). Mutations needed to confer 
higher affinity could have unexpected effects on protein expression from the Ad 
delivered IgG DNA or biodistribution of the IgG, thus making it difficult to predict how 
protection to pathogen challenge might be affected. A scFv fragment incorporating the 
VH and VL domains of the 2C14.4 IgG was constructed and subjected to affinity 
maturation by screening a library generated by random mutagenesis for high affinity 
variants. The latter was performed using an E. coli display technique called Anchored 
Periplasmic Expression (APEx) coupled with fluorescent activated cell sorting (FACS) 
(59). In APEx, the protein library is tethered to the periplasmic side of the inner 
membrane of the bacterium via fusion to the 6 N-terminus amino acids of the native 
lipoprotein NlpA. The resulting NlpA-scFv fusion is lipidated in vivo and thus becomes 
attached to the inner membrane. Following permealization of the E. coli outer membrane 
by chemical and enzymatic means, the cells are labeled with fluorescent antigen and the 
brightest cells are isolated by FACS. A single round of random mutagenesis and APEx 
screening resulted in the isolation of a clone, H8, displaying a KD=100 pM which is 35-
fold higher affinity than the parental 2C14.4. The H8 VH and VL domains were used to 
exchange those of 2C14.4 IgG in the adenoviral vector AdαV giving rise to AdαH8. We 
show that delivery of the two vectors in vivo resulted in approximately the same Ab 
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serum titers and that mice immunized with 1010 pu AdαH8 conferred a statistically 
significant increase in protection relative to the parental AdαV. 
 
RESULTS 
Engineering high affinity anti-V antigen antibodies 
The variable heavy chain (VH) and light chain (VΚ) domains of the Y. pestis 
neutralizing mAb 2C12.4 were amplified by PCR (149) and used to create a single chain 
variable fragment (scFv) by incorporating a sequence encoding a (Gly4Ser)4 linker 
between the C termini of the VH sequence and the N termini of the VΚ sequence. The 
gene encoding the scFv was cloned into pMoPac16 for soluble expression of the antibody 
fragment in the single chain antibody (scAb) format (65). The scAb format is comprised 
of a scFv in which the C termini of the variable light chain domain is fused to the human 
kappa constant domain, resulting in improved expression characteristics in E. coli 
without altering the antibody binding affinity (62). Lysates from cells expressing the 
2C14.4 scAb were confirmed to express full length protein via Western blotting and 
displayed binding activity as determined via ELISA using purified Y. pestis V antigen. 
The gene encoding the scFv version of 2C12.4 was subjected to one round of 
random mutagenesis by error-prone PCR. Amplified DNA was cloned into pFLAG-
APEx and the ligation product was transformed into E. coli Jude-1 cells yielding >2 X 
106 independent transformants. DNA sequencing of 10 clones selected at random 
revealed an average of 1.75% nucleotide substitutions with a standard deviation of 
0.75%. Cells were grown in liquid culture, protein expression was induced, and 4 hours 
later, the cells were harvested and converted into spheroplasts. The spheroplasted cells 








































































Figure 4.1.  Schematic diagram of APEx 
Libraries of antibody fragments are expressed from a single plasmid (pFLAG-APEx) as 
N-terminal fusions to NlpA(1-6) and are anchored to the periplasmic face of the 
cytoplasmic membrane of E. coli. This vector also encodes for a C-terminal FLAG 
epitope peptide. The cells are converted to spheroplatst through chemical and enzymatic 
degradation of the outer membrane and peptidoglycan layer allowing fluorescently 
labeled exogenous antigen to interact with the antibodies displayed on the surface of the 
inner membrane. Spheroplasts containing antibodies specific for the antigen are enriched 
from the total population by FACS and their antibody genes recovered by PCR. 
determine full-length scFv expression levels and antigen binding, respectively (Figure 
4.1). A total of 8 X 107 cells (40-fold library coverage) were subjected to high-throughput 
fluorescence activated cell sorting (FACS) and the top 2% events in terms of PE and 
BODIPY fluorescence emissions were collected (Figure 4.2). The collected spheroplasts 
were immediately resorted as above without additional labeling to maximize the isolation 
of antibodies with slow dissociation rate constants toward V antigen (59). The scFv genes 
in the spheroplasts collected during the resort were amplified by PCR, and the DNA was 
subcloned back into the pFLAG-APEx vector. Following transformation, the cells were 
subjected to two additional rounds of sorting using increasingly stringent collection 
criteria, namely a higher fluorescence threshold. After the third round of sorting, the 
number of events falling within the window used for the 1st round increased from 2% to 
23% (Figure 4.2). 
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Antigen Binding  
Figure 4.2.  FACS analysis of affinity maturation using APEx. 
FACS analysis of E. coli spheroplasts expressing anti-V antigen 2C12.4 scFv, the library 
of random mutants, and the populations recovered following two rounds of FACS. 
Spheroplasts were labeled with 500 nM V antigen-BODIPY and 5 μg/ml anti-FLAG-PE. 
The dashed box represents the gate used to isolate cells by FACS from the original 
library. The percentage of the spheroplast in this gate for each population is indicated. 
The scFv gene pool from the third round of sorting was amplified by PCR and 
cloned into pMoPac16 for expression in the scAb format. SPR was used to rank order the 
dissociation rate constants of individual clones in crude cell lysate (Figure 4.3). Of the 72 
colonies tested, 41 (57%) expressed scAbs that displayed significant binding towards V 
antigen immobilized on the Biacore chip. Of these 41 clones, four clones exhibited 
dissociation rate constants at least 10-fold slower than parental antibody (Figure 4.4). The 














Cells expressing soluble antibodies
 
 93






















Relative   
koff
2C12.4 3.9 X 10-4 1
G8 2.8 X 10-5 14
F4 3.5 X 10-5 11
E4 2.7 X 10-5 20
H8 < 5 X 10-6 >75
 
Figure 4.4.  SPR analysis of four clones with low koff
Crude cell lysates containing scAbs from 72 different clones were analyzed by SPR to 
determine their dissociation rate constants. Accurate values for H8 were not determined 





koff Relative   
to Purified
Purified 3.2 X 10-4 1.0
Run 1 3.3 X 10-4 1.0
Run 2 3.9 X 10-4 1.2
Run 3 4.0 X 10-4 1.3























Figure 4.5.  Reproducibility of koff analysis by SPR 
Four colonies each expressing 2C12.4 scAb were individually picked and processed 
according to the method described here. The dissociation rate constant for each sample 
was compared to the actual value obtained using purified 2C12.4 scAb monomers. 
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These four scAbs, as well as the 2C141.4 and 26.10 scAbs, were expressed at the 
500 ml scale in shake flasks, the periplasmic fraction was isolated by osmotic shock, and 
monomeric scAb proteins were purified by immobilized metal affinity chromatography 
(IMAC) and size exclusion FPLC. Consistent with the isolation of the respective clones 
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based on increased PE fluorescence, the protein yields for all four scAbs was higher than 
that of the parental 2C14.4 scAb (Table 1). All antibodies exhibited at least 10-fold lower 
equilibrium dissociation constants (KD) relative to the parental 2C14.4 scAb (Table 4.1) 
which is consistent with the measurements obtained using crude cell lysates (Figure 4.5). 
The highest affinity clone, H8, exhibited an affinity of 100 pM that translates to a 35-fold 
improvement compared to the parental antibody 2C12.4. The improved affinity for all 
clones was almost exclusively the result of a decrease in the dissociation rate constant 
whereas the association rate constant remained essentially unchanged. The four variants, 
H8, E4, F4 and G8, contained either 7 or 9 amino acid mutations compared to the 
parental antibody (Table 4.2) of which two were common: L49S in framework 2 of the 
VH, which is immediately prior to complementary determining region 2 (CDR2); and 
Y32F in CDR1 of the light chain (102). Further, three of the variants contained an 
additional four common mutations (D1N, T5S, R24K, T97R) in the light chain. 
 
Table 4.1. Kinetic analysis of anti-V antigen antibody fragments 
Antibody 
kon          
(M-1s-1) 
koff         
(s-1) 






2C12.4 9.2 X 104 3.2 X 10-4 3500 1x 1x 
H8 1.2 X 105 1.2 X 10-5 100 35x 4x 
E4 1.0 X 105 1.8 X 10-5 180 20x 5x 
F4 1.2 X 105 2.6 X 10-5 220 16x 3x 
G8 9.8 X 104 2.4 X 10-5 250 14x 2x 
aAffinity improvement relative to the parental antibody 2C12.4 
bYield of purified scAb (mg/L A600) compared to 2C12.4 
 
Table 4.2.  Sequence analysis of anti-V antigen antibody fragments 
                          Variable Heavy Chaina               Variable LightChaina
3 11 32 45 49 51 65 67 82 1 5 24 32 39 53 72 84 97
2C12.4 T I S L L I S L I D T R Y K N T A T
H8 S V N S K F R
E4 V P S F R S T
F4 A P S V N S K F R

























aAmino acid substitutions based on Kabat numbering (102). FW, framework; CDR, 
complementary determining region 
 
Genetic immunization using IgG encoding adenovirus vectors and challenge with Y. 
pestis 
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The VH and VΚ domains of a replication-defective serotype 5 human Ad gene 
transfer vector encoding the 2C12.4 mouse IgG2b (AdαV) were replaced with those from 
the highest affinity antibody variant, H8, to create AdαVH8 (149). Mice were immunized 
with varying numbers of particle units (pu) of AdαV, AdαVH8, or, as controls with 
either the highest level (1011 pu) of AdαPA, an adenovirus vector encoding a mouse IgG 
mAb specific for the B. anthracis PA or PBS. Serum anti-V antigen antibody titers were 
measured via ELISA three days post immunizations (Figure 4.6). A similar dose 
dependent response was observed for both AdαV and AdαVH8. The titers for equivalent 
immunization levels were within 2-fold for both AdαV and AdαVH8. Both AdαPA and 
PBS controls did not result in any measurable anti-V antibody titers. Three days after 
immunization, the mice were challenged intranasally with 363 LD50 of Y. pestis CO92 
(Figure 4.7). All mice immunized with the highest dosage (1011 pu) of AdαV and  
AdαVH8 survived. However, at a 10-fold lower dose (1010 pu), none of the mice 
immunized with AdαV survived while 80% (4 out of 5, P < _) of the mice immunized 
with this dose of AdαVH8 survived. None of the mice immunized with the lowest dose 





































Figure 4.6.  Mice titers following immunization with Ad vectors 
Anti-V antigen IgG titers in mice following immunization with Ad vectors. C57BL/6 
mice (n = 5/group for AdαV and AdαVH8; n = 1/group for AdαPA and PBS) were 
administered intravenously with the indicated Ad vectors or PBS. Serum anti-V antigen 
antibody titers were measured three days post immunization via ELISA. PBS, negative 
control; AdαPA, vector encoding an IgG specific for the B. anthracis PA; AdαV, vector 


































































Figure 4.7.  Survival of mice challenged with Y. pestis 
Survival of mice challenged with Y. pestis following prophylactic administration of Ad 
vectors. Three days following intravenous administration of Ad vectors or PBS, C57BL/6 
mice (n = 5/group for AdαV and AdαVH8; n = 1/group for AdαPA and PBS) were 
challenged with a lethal dose of Y. pestis intranasally. Survival of the mice was monitored 
for 14 days following challenge. (A) Immunization with AdαV compared to AdαPA and 
PBS. (B) Immunization with AdαVH8 compared to AdαPA and PBS. 
 
DISCUSSION 
 Passive immunization with engineered antibodies displaying enhanced 
antigen affinity have been shown to increase the neutralization efficacy of a number of 
bacterial or viral pathogens and toxins (5, 101, 105, 126, 131, 162). However, to the best 
of our knowledge, neither the effect of antigen affinity for antibodies expressed in situ 
following viral transfer of the antibody gene, nor the relationship between V antigen 
affinity and protection to the potential biowarfare agent Y. pestis, have been examined. 
Here we found that increasing the affinity of the Y. pestis neutralizing antibody 2C14.4 
from 3.5 nM to 100 pM (35-fold) could confer significant protection against a lethal 
challenge with Y. pestis at a 10-fold lower viral load for genetic delivery of the antibody.  
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The affinities of antibodies generated by the natural immune system are 
constrained by the kinetics of in vivo selection (45). Most high affinity mouse 
monoclonal antibodies display nanomolar affinities and this is the case for the anti-V 
antigen antibody 2C12.4 for which we measured a KD=3.5 nM by SPR. Combinatorial 
mutagenesis and library screening by phage display or other high throughput techniques 
has been employed for affinity maturation of the variable domains of monoclonal 
antibodies (5, 101, 105, 126, 131, 162). In earlier studies, we used random mutagenesis 
and screening of E. coli displayed libraries by APEx to isolate picomolar affinity 
antibodies to the B. anthracis PA which in turn proved to have markedly improved 
neutralization potency in vitro and in various animal models (98, 105, 115). Key 
advantages of this strategy are the ease with which libraries of random mutants can be 
constructed in E. coli and screened by FACS. FACS is a high-throughput screening 
technique that enables real-time quantitative multi-parameter analysis on a cell by cell 
basis. Therefore, multiple properties can be monitored simultaneously to specifically 
isolate antibodies with desired characteristics.  
In this work antibody fragments were tagged with a C-terminal FLAG peptide 
epitope that allowed simultaneous monitoring of both antigen affinity (using V-antigen 
labeled green) and expression level (using an anti-FLAG antibody labeled red, Fig. 1). 
Clones isolated from the last round of FACS were rank-ordered by comparing the 
dissociation rate constants in crude lysates (Supplementary Fig. 1). This approach 
significantly expedited the analysis of the clones obtained after screening, a process that 
often represents the rate limiting step in antibody affinity maturation. While it was not 
necessary to use in this case, the relative expression levels of the antibody variants can 
also be determined in high throughput using a 96-well dot blot apparatus and the data can 
then be used to estimate the association rate constant (kon) (data not shown). In the end, a 
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single round of mutagenesis following by three rounds of FACS and dissociation rate 
constant analysis resulted in the isolation of antibodies displaying up to 35-fold higher 
affinities and higher expression yields (Fig. 1B, Table 1). 
Genetic delivery of full-length antibodies in vivo has been carried out using 
adenovirus, adeno-associated virus and vaccinia virus vectors (9, 44, 82) and is an 
attractive alternative to the high cost of conventional methods which require production, 
purification, and storage of the monoclonal antibody (35, 82). This is compounded by 
problems relating to administration, bioavailability, and increased immunogenicity 
resulting from large dosages required by conventional methods (139). The administration 
of most monoclonal antibodies treatments requires hour long intravenous infusions every 
one to four weeks in order to maintain clinically relevant serum concentrations during 
this period (REF). A common complication are infusion reactions with symptoms ranging 
from mild to life-threatening and typically occur near the time of administration (31). 
Following infusions, complicated pharmacokinetics result in a continual decrease in 
serum concentrations which effects the bioavailability and the pharmacodynamic 
properties of the therapeutic antibody (83, 139). In addition, the initial large dosages 
required during infusions also increase the probability of generating an immune response 
against the therapeutic monoclonal antibody which can lead to rapid elimination and 
potentially severe allergic reactions (139). However, genetic delivery can provide 
immediate and sustained serum levels for several months from a single treatment with 
both adenovirus (Ad) and adeno-associated virus (AAV) vectors encoding the same 
monoclonal antibody (18). This approach has been demonstrated with a neutralizing 
antibody and offered almost immediate protection against anthrax toxin challenge in vivo 
which was sustained for 6 months (40). This approach circumvents many of the issues 
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associated with conventional methods and has the additional benefits of increasing 
patient quality of life and protecting soldiers entering combat for extended periods. 
Here we demonstrate for the first time that the affinity of antibodies produced in 
situ following adenoviral gene transfer correlates with protection. Although the affinity of 
the antibody was improved 35-fold, only a 10-fold reduction in viral load could confer 
significant protection against a lethal challenge with Y. pestis in vivo. This was 
significant, but the lack of a direct correlation between affinity and efficacy may result 
from a decrease in antibody specificity attributed to a lysine to arginine substitution 
found in the affinity enhanced mutant (15). Arginine residues are correlated with 
increased non-specific binding which can alter biodistribution and result in this lower 
than expected viral load reduction of the mutant. 
Engineering ultra-high affinity antibodies for in situ delivery may be one 
approach to circumvent preexisting immunity against Ad. Although human Ad serotype 
5(Ad5) has been effectively used in a variety of animal models for genetic delivery, it has 
limited use because approximately 35 to 50% of humans have preexisting neutralizing 
antibodies against it (61). Even though human and non-human based Ad vectors can be 
effective in genetic delivery even in the presence of preexisting immunity, cross-reactive 
antibodies have been reported and are a major obstacle limiting the widespread use of Ad 
vector for gene therapy (61). An approach that has yet to be explored is to minimize the 
genetic delivery dosage levels in order to evade host immunity. This has been shown to 
occur when a low-dose infection with Salmonella evades host adaptive immunity (150). 
Ultra-high affinity antibodies have been reported (16) and may require very low Ad 
vector dosages that evade preexisting immunity while maintaining 
prophylactic/therapeutic benefit. The dosage levels can be further reduced by 
simultaneously engineering the Ad vectors to increase serum titers of the antibody for 
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which they encode (18). This combination approach can increase the application potential 
of the genetic delivery of antibodies as well as other proteins. 
There are many pathogens to which an effective vaccine or antibiotic has yet to be 
produced and monoclonal antibodies remain the only alternative for protection. These 
antibodies frequently require engineering to enhance their affinities and expression levels 
in order to make them effective prophylactics/therapeutics from both a cost and efficacy 
perspective. This requires display systems and screening methodologies to expedite the 
discovery and engineering process. Even if a therapeutic antibody is generated, 
conventional methods for antibody production are expensive and high costs associated 
with therapy minimize their practical applications. However, genetic delivery of 
antibodies is an attractive alternative since it has the potential to be cheaper, safer, and 
increase patient quality of life. 
 
MATERIALS AND METHODS 
Bacterial strains and plasmid vectors 
Escherichia coli Jude-1 (E. coli DH10B F- mcrA Δ(mrr-hsdRMS-mcrBC) 
φ80dlacZ ΔM15 ΔlacX74 recA1 araD139 Δ(ara leu)7697 galU galK rpsL endA1 nupG 
harboring an F′ from E. coli XL1-blue introduced by conjugation) used for all antibody 
engineering experiments. Plasmid pMoPac16 was used for soluble single-chain antibody 
fragment (scAb) expression and has been previously described (65). Plasmids pAPEx1 
was used for E. coli display of soluble single-chain variable fragment antibodies (scFv) 
(59). pFLAG-APEx was constructed by replacing the polyhistidine and c-myc sequences 
in pAPEx1 via BamHI and NotI restriction sites with the FLAG peptide epitope sequence 
amplified by PCR using primers TVB100 (5’-
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GTCGCTGCGGCCGCAGATTACAAAGACGACGATGACAAGTAGTGATATCGCA
AGCTTGACC-3’) and TVB101 (5’-
CAGCGAGGATCCGTGACGCAGTAGCGGTAAACGGC-3’).  
 
Protein expression and purification 
Recombinant V antigen was expressed and purified as previously described (149). 
Monomeric scAbs were expressed and purified according to published procedures (59, 
65). Briefly, E. coli Jude-1 containing pMoPac16 derivatives encoding the desired scAb 
genes were streaked from frozen stocks onto agar plates containing Luria-Burtani Miller 
(LB) medium (Becton Dickinson Difco™, Sparks, MD) supplemented with 2% (wt/vol) 
glucose (2% glc) and 200 μg/ml ampicillin (Amp200) (20 h, 25 ºC). Individual colonies 
were cultured in 2 ml of Terrific Broth (TB) medium (Becton Dickinson Difco™, Sparks, 
MD) + 2% glc + Amp200 (8 h, 250 rpm, 30 ºC) then 1 ml was used to inoculate 500 ml 
of TB medium + 2% glc + Amp200 (250 rpm, 30 ºC). After overnight growth, cells were 
pelleted by centrifugation (15 min, 4,400 X g, 4 ºC) and resuspended in 500 ml of TB 
medium + Amp200 + 1 mM Isopropyl-β-d-thiogalactopyranoside (IPTG) (Sigma-
Aldrich, St. Louis, MO) to induce protein expression. After 4 h of incubation at 25 ºC, 
the cells were pelleted by centrifugation (15 min, 4,400 X g, 4 ºC), and the periplasmic 
fraction from the cell pellet was isolated by osmotic shock according to published 
procedures (65). scAb proteins were purified from the shockate by immobilized metal 
affinity chromatography (IMAC) using Ni-NTA Agarose based on the manufacturer’s 
protocol (Qiagen, Hilden, Germany), and monomeric scAbs were further isolated by size-
exclusion FPLC (SEC) on a SuperdexTM 200 column (GE Healthcare, Uppsala, Sweden) 
using HBS-P (GE Healthcare, Uppsala, Sweden). Proteins were quantified based on the 
A280 measured using a NanoDropTM 1000 (Thermo Fisher Scientific, Wilmington, DE) 
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and the appropriate extinction coefficients calculated using Protein Calculator 
(http://www.scripps.edu/~cdputnam/protcalc.html, Putnam Lab at The Scripps Research 
Institute, La Jolla, CA). Relative concentrations were verified and purity determined by 
SDS-PAGE using a 4-20% gel (NuSep, Lawrenceville, GA) stained with GelCode Blue 
(Thermo Fisher Scientific, Rockford, IL). All scAbs used in this work were at least 90% 
pure.  
 
Anti-V antigen antibody fragment cloning, expression, and analysis 
Genes encoding the variable heavy chain (VH) and the variable light chain (VΚ) 
domains of anti-V antigen 2C12.4 IgG were amplified by PCR from the previously 
described adenovirus vector plasmid DNA (149) using primers TVB102 (5’-
GCAGCGAGGCCCAGCCGGCCATGGCGCAGGTAACTCTGAAAGAGTCTG-3’) 
and TVB103 (5’-AGAGCCGCC 
GCCGCCGCTACCACCACCACCAGAACCACCACCACCTGAGGAGACTGTGAGA
GTGGTG-3’) for VH and TVB104 (5’-
GGTGGTGGTGGTAGCGGCGGCGGCGGCTCTGGCGGCGGCGGCTCCGACATTG
TGCTGACAC AGTCG-3’) and TVB105 (5’-
CGAATTCGGCCCCCGAGGCCCGTTTTACTTCCAGCTTGGTC-3’) for VΚ (149). 
The resulting PCR products were combined by overlap extension PCR and cloned into 
pMoPac16 via the non-compatible SfiI restriction sites for soluble expression as a scAb. 
The resulting ligation product was transformed into E. coli Jude-1, and scAb expression 
was performed as previously described (29, 65). Briefly, individual colonies were 
cultured overnight in 2 ml of TB medium + 2% glc + Amp200 at 30 °C. After overnight 
growth, cells were pelleted by centrifugation (10 min at 4,600 X g, 4 ºC) and resuspended 
in 2 ml of TB medium + Amp200 + 1 mM IPTG to induce protein expression. After 4 h 
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incubation at 25 ºC, 1 ml of cells were pelleted by centrifugation (10 min at 4,600 X g, 4 
ºC), and the cell pellet was resuspended in 1 ml of lysis buffer which consisted of 
BugBusterTM HT Protein Extraction Reagent (Novagen, Madison, WI) diluted 1:4 in 
phosphate buffered saline (PBS) (107). The cells were incubated in lysis buffer while 
rotating on an inverter (30 min, 60 RPM, 25 ºC) then the insoluble fraction was removed 
by centrifugation (1 min, 10,000 X g, 4 ºC). 
The soluble fraction was analyzed for the presence of full-length scAb specific for 
the V antigen by Western blot analysis and enzyme-linked immunosorbent assay 
(ELISA), respectively. Western blot analysis with anti-polyhistidine (anti-His) peroxidase 
(HRP) conjugate (Sigma-Aldrich, St. Louis, MO) was performed as previously described 
(132). ELISA was performed by coating Costar® high binding 96-well EIA/RIA plates 
(Corning, Corning, NY) overnight at 4º C with 50 μl of 5 μg/ml recombinant V antigen 
or bovine serum albumin (BSA) in PBS. The plates were washed three times with PBS 
followed by blocking with 400 μl PBS supplemented with 2% milk for 4 h at room 
temperature. Samples were diluted 1:1 in PBS with 2% milk and incubated for 1 h at 
room temperature. The plates were washed three times with PBS then an additional three 
times with PBS containing 0.1% Tween-20. Immunocomplexes were detected using an 
anti-human kappa light chain (anti-HuCκ) polyclonal serum HRP conjugate (Sigma, St. 
Louis, MO) applied at a 1:10,000 dilution and incubated for 30 min at room temperature. 
The plates were washed as described above and developed using the chromogenic HRP 
substrate TMB+ (Dako, Glostrup, Denmark) as described by the manufacturer. The A450 
was measured with a mircroplate reader (BioTek, Winooski, VT). 
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Isolation of high affinity variants of the 2C14.4 scFv 
The anti-V antigen 2C12.4 scFv and the anti-digoxin 26.10 scFv were cloned into 
pAPEx1 and pFLAG-APEx via the non-compatible SfiI restriction sites; E. coli Jude-1 
transformed with the respective ligation products were used as controls for flow 
cytometry experiments (59). Purified recombinant V antigen was conjugated to 
BODIPY® using 6-((4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-diaza-s-indacene-3-
propionyl)amino)hexanoic acid succinimidyl ester (Invitrogen, Carlsbad, CA) at a molar 
ratio of 1:5 as described by the manufacturer. Free BODIPY FL-X SE was removed 
using a NAP-10 gel filtration column as described by the manufacturer (GE Healthcare, 
Uppsala, Sweden). The extent of conjugation was determined based on the ratio of A280 
and A504 measured using a NanoDropTM 1000 and the appropriate extinction coefficients 
and correction factors as recommended by the manufacturer (Invitrogen, Carlsbad, CA; 
http://www.scripps.edu/~cdputnam/protcalc.html, Putnam Lab at The Scripps Research 
Institute, La Jolla, CA). 
The anti-V antigen 2C12.4 scFv was subjected to random mutagenesis by error-
prone PCR (50), the amplified DNA was cloned into pFLAG-APEx via the non-
compatible SfiI restriction sites, and the ligation product was transformed into 
electrocompetent E. coli Jude-1 (59). Cells were cultured on agar plates containing LB 
medium + 2% glc + 30 μg/ml chloramphenicol (Cm30) (22 h, 25 ºC). Cells were 
transferred to LB medium + 2% glc + 15% glycerol (v/v) to A600 ~10 then stored at -80 
ºC. Frozen cell stocks were thawed on ice and subcultured to A600 0.1 in TB medium + 
2% glc + Cm30 at 37 ºC, grown to A600 ~0.8-1.2, cooled for 30 min to 25 ºC, and protein 
expression was induced with the addition of 1mM IPTG. After 4h induction at 25 ºC, 1 
ml of cells at A600 5.0 were converted to spheroplasts using 
Tris/Sucrose/EDTA/lysozyme as previously described (59, 107). The spheroplasted cells 
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were first labeled with 5 μg/ml PhycoLink® anti-Flag® R-Phycoerythrin (anti-Flag PE) 
(Prozyme, San Leandro, CA) in PBS supplemented with 1% BSA (PBSB) (30 min, 150 
rpm, 25 ºC). The spheroplasts were washed with PBSB and labeled with 500 nM V 
antigen conjugated to BODIPY (V antigen-BODIPY) in PBSB (1 h, 150 rpm, 25 ºC). 
Labeled spheroplasts were washed with PBSB and analyzed on a FACSAria (Becton 
Dickinson Biosciences, San Jose, CA) droplet deflection flow cytometer by exciting with 
a 488-nm laser and measuring the fluorescence emission spectrum of BODIPY and PE 
with 530/40 and 570/40 band-pass filters, respectively. Fluorescence compensation was 
performed using the APEx controls as previously described (107). The library population 
was gated to avoid aggregates as determined by the forward scatter (FSC) and side scatter 
(SSC) parameters, and the brightest 1-2% of the population based on both the BODIPY 
and PE emission spectrums was collected (59, 107). The collected spheroplasts were 
immediately resorted, and the scFv genes in the resort solution were by amplified by PCR 
using primers BRH06 (5’-GCGGATAACAATTTCACACAGG-3’) and AHX89 (5’-
CGCAGTAGCGGTAAACGGC-3’) (59). The amplified DNA was cloned into pFLAG-
APEx via the non-compatible SfiI restriction sites, and the ligation mixture was 
transformed into electrocompetent E. coli Jude-1. At least 10-fold excess of colonies 
relative to the number of events in the resort were obtained. Colonies were scraped from 
the agar plates into liquid media as above and subjected to an additional two rounds of 
sorting exactly as described above. 
The scFv genes from the third round of sorting were subcloned into pMoPac16, 
and the ligation product was transformed into E. coli Jude-1 for expression of soluble 
scAb similar to above (59). In addition, E. coli Jude-1 containing pMoPac16 encoding 
2C12.4 scAb was streaked from a frozen stock onto an agar plate containing LB medium 
+ 2% glc + Amp200. Further, the anti-digoxin 26.10 scFv was cloned into pMoPac16 via 
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the non-compatible SfiI restriction sites, and the ligation product was transformed into E. 
coli Jude-1. 72 individual colonies from round III, 8 colonies of 2C12.4 scAb and 4 
colonies of 26.10 scAb were picked and cultured overnight in sterile Costar® round 
bottom 96-well microtiter plates (Corning, Corning, NY) containing 200 μl of TB 
medium + 2% glc + Amp200 on a microtiter plate shaker. After overnight growth (150 
rpm, 30 ºC), 4 μl aliquots were transferred to a master microtiter plate containing 156 μl 
of TB medium + 2% glc + Amp200, cultured on a plate shaker (8 h, 150 rpm, 30 ºC) and 
stored at 4 ºC for up to two weeks. The remaining cells were pelleted by centrifugation 
(10 min at 4,600 X g, 4 ºC) and resuspended in 200 μl of TB medium + Amp200 + 1 mM 
IPTG to induce protein expression. After 4 h induction at 25 ºC, cells were pelleted by 
centrifugation (10 min at 4,600 X g, 4 ºC), the cell pellet was resuspended in 1 ml of lysis 
buffer for 30 min at 25 ºC, and the insoluble fraction was removed by centrifugation (20 
min at 4,600 X g, 4 ºC). The soluble fraction was further clarified using 96-well 
MultiScreen® HTS NA clearing filter plates (Millipore, Billerica, MA) as described by 
the manufacturer. Filtered lysates were transferred to Costar® non-binding 96-well plates 
(Corning, Corning, NY) and covered with microplate foil (GE Healthcare, Uppsala, 
Sweden). Relative expression levels of scAbs in filtered lysate were obtained using a 
Minifold® I Dot Blot System (Whatman, GE Healthcare, Uppsala, Sweden) by 
transferring 10 μl of filtered lysate diluted with 90 μl of PBS to a nitrocellulose 
membrane following the manufacturer guidelines. Western blot analysis of the 
nitrocellulose membrane was performed with anti-His HRP conjugate as previously 
described (132). The scAbs in filtered lysate were analyzed by SPR as described below. 
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Surface Plasmon resonance (SPR) 
The scAbs in filtered lysate were analyzed via SPR using a BiacoreTM 3000 (GE 
Healthcare, Uppsala, Sweden) to obtain accurate dissociation rate constants of the 
scAb:V antigen complexes. Approximately 200 response units (RU) of V antigen in 10 
mM sodium acetate, pH 5.0 were coupled to a CM5 chip (GE Healthcare, Uppsala, 
Sweden) by using 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide/N-hydroxy 
succinimide chemistry. BSA was similarly coupled to the chip and used for in-line 
subtraction. Kinetic analysis was performed in HBS-P (GE Healthcare, Uppsala, Sweden) 
at a flow rate of 25 μl/min at 25 ºC unless indicated. Samples were injected for 3 min and 
dissociation was monitored for 5 min. The surface was regenerated with two 12 sec 
injections of 50 mM phosphoric acid. The antigen binding kinetics of purified monomeric 
scAb were determined in HBS-P at a flow rate of 50 μl/min. Samples were injected for 2 
min and dissociation was monitored for 10 min. The surface was regenerated with two 12 
sec injections of 50 mM phosphoric acid. Four 2-fold dilutions of each antibody 
beginning at 160 nM were performed in triplicate, double referenced with a blank, and 
globally fit to a 1:1 Langmuir binding model for the calculation of both kof and koff using 
BIAevaluation software (GE Healthcare, Uppsala, Sweden) (116). 
 
Ad vectors 
AdαV is a replication-defective human adenovirus (Ad) serotype 5, E1-E3- gene 
transfer vector constructed to direct the expression of the heavy and light chains of the 
anti-V antigen monoclonal antibody 2C12.4 from a single promoter (149). The 
expression cassette contains (5' to 3') the cytomegalovirus (CMV) immediate early 
promoter/enhancer, the antibody IgG2b heavy chain gene, a 4 amino acid furin cleavage 
site, the 24 amino acid self-cleaving 2A peptide, the kappa light chain gene, and the 
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simian virus (SV) 40 polyadenylation signal. AdαV.H8 was constructed by assembling 
the genes encoding the variable heavy chain (VH) and variable light chain (VΚ) domains 
of the high affinity anti-V antigen 2C12.4 variant, H8, by overlap PCR using the AdαV 
IgG2b expression cassette as a template and the resulting fragment was used to replace 
the 2C12.4 coding sequence in AdαV. AdαPA is a similarly constructed gene transfer 
vector encoding an unrelated antibody (14B7-1H) against Bacillus anthracis protective 
antigen (PA) and was used as a negative control (40). AdαV, AdαV.H8, and AdαPA were 
produced in human embryonic kidney 293 cells (American Type Culture Collection, 
Manassas, VA) and purified by centrifugation twice through a CsCl gradient as described 
(137). The titer of each recombinant Ad preparation was determined 
spectrophotometrically and expressed as particle units (pu) as described (114). 
 
Assessment of AdαV in vivo 
Male C57BL/6 mice (n=5/group) (The Jackson Laboratory, Bar Harbor, ME) 
were housed under specific-pathogen-free conditions and used at 6 to 8 weeks of age. 
Mice were administered AdαV or AdαV.H8 (109, 1010, or 1011 pu) via the intravenous 
route. Naïve mice or mice injected with AdαPA (1011 pu) were used as negative 
controls. Ad vectors were diluted with saline to the specified dose. Serum was collected 
via the tail vein three days following vector administration, centrifuged at 8000x g for 20 
min, and stored at -20 °C. Anti-V antigen serum titers were assessed by ELISA using flat 
bottomed 96-well EIA/RIA plates (Corning, New York, NY) coated with 100 μl 5 μg/ml 
recombinant V antigen in 0.05 M carbonate buffer, pH 7.4 overnight at 4 °C. The plates 
were washed with PBS containing 0.05% Tween-20 (PBST) and blocked with 400 μl 
PBS supplemented with 5% milk for 1 hr at 23 °C. Serial serum dilutions were added to 
each well and incubated for 1 hr at 23°C. The plates were washed four times with PBST, 
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immunocomplexes were detected using a sheep anti-mouse IgG HRP conjugate (Sigma, 
St. Louis, MO) applied at a 1:10,000 dilution in PBS supplemented with 1% milk 
incubated for 1 hr at 23 °C. The plates were washed four times with PBST and once with 
PBS, developed using 100 μl of peroxidase substrate (Bio-Rad, Hercules, CA) incubated 
for 15 min at 23 °C, and the reaction quenched by the addition of 100 μl 2% oxalic acid. 
The A415 was measured with a microplate reader (Bio-Rad, Hercules, CA). Antibody 
titers were calculated based on log(optical density)-log(dilution) normalized with purified 
anti-V antigen antibodies to account for affinity differences. Mice challenge studies were 
conducted at The Public Health Research Institute (PHRI) at the International Center for 
Public Health (Newark, NJ) under biosafety level 3 (BSL3) conditions. Y. pestis CO92 
was grown aerobically in Heart Infusion Broth (Becton Dickinson DifcoTM, Sparks, 
MD) at 30 °C and diluted in saline solution for a challenge dose of 2 x 104 cfu which 
corresponds to 363 LD50. Twenty-five μl of bacterial suspension was used for intranasal 
infection of mice; bacterial dose was controlled by plating on Yersinia Selective Agar 
(YSA) (Oxoid, Hampshire, UK) and counting colonies for cfu determination. Survival 
was monitored daily for 14 days. 
 
Statistical analysis 
The data are presented as mean ± standard error of the mean. Statistical analyses 
were performed using the non-paired two-tailed Student's t-test, assuming equal variance. 
Survival evaluation was carried out using Kaplan-Meier analysis. Statistical significance 
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Conclusions and Future Directions 
 
CONCLUSIONS 
This dissertation describes the implementation of a novel combinatorial library 
screening technology for the discovery and engineering of antibodies with unique binding 
properties. The anchored periplasmic expression (APEx) technology, as it is known, 
relies on anchoring antibody fragments onto the periplasmic side of the inner membrane 
of E. coli via fusion to either a transmembrane domain of an integral membrane protein 
or to the signal peptide and the first few N-terminal amino acids of an inner membrane 
lipoprotein, such as NlpA (59, 79). For the detection and subsequent isolation of antigen 
specific antibody fragments, the cells are converted to spheroplasts in order to disrupt the 
outer membrane and peptidoglycan layer, incubated with a fluorescently labeled antigen, 
and isolated by fluorescence activated cell sorting (FACS) based on high fluorescence. 
The APEx technology is also amenable for the isolation of full-length antibodies which 
assemble in the periplasm into aglycosylated IgGs that are fully functional for antigen 
binding and are non-covalently captured onto the inner membrane by an IgG binding 
protein co-expressed using APEx (106).  
The limitations and relative merits of using different antibody formats in the 
combinatorial libraries by APEx was examined. The diversity of antibody binding sites 
obtained when the same library of VH and VL domains from an immunized animal was 
formatted as either an IgG or as a scFv was compared (Chapter 2). The two libraries were 
screened by APEx using similar cell labeling and FACS conditions, and a small panel of 
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antibodies specific for the Protective Antigen (PA) component from Bacillus anthracis, 
the causative agent of anthrax, were isolated. Overall, IgG display resulted in the 
isolation of a broader panel of VH and VL domain sequences exhibiting a wide range of 
affinities (KD=21-440 nM), although, a binding site with a slightly higher affinity (KD=6 
nM) was isolated from the scFv library. Notably, several V domains isolated as IgGs 
displayed substantially reduced affinity when expressed as antibody fragments, which 
explains why they were not recovered from the scFv library. The results indicate that the 
antibody format used during in vitro selection affects which antibody variable domains 
can be isolated during screening. Therefore, the format required for the final application 
of the antibody is the preferred format for library generation and screening. 
Several modifications of the APEx methodology were developed to allow for 
more efficient recovery of antibodies with desired properties (Chapter 3). Specifically, 
the system was reengineered to simultaneously account for antibody binding and 
expression levels by incorporating a C-terminal epitope peptide. The C-terminal epitope 
is recognized by a fluorescently labeled antibody for the detection of protein expression. 
This system, referred to as FLAG-APEx, was used to examine the effects of converting 
E. coli to spheroplasts and led to the development of optimal FACS settings. The 
combination of simultaneous detection of antibody binding and expression levels coupled 
with optimized FACS settings was shown to enable the isolation of antigen specific 
antibodies in a more efficient manner. Furthermore, additional strategies for protein 
display in E. coli were discovered (Chapter 3). Particularly, soluble proteins expressed in 
the periplasm of E. coli were found to be retained following conversion to spheroplasts. 
The degree to which soluble proteins were retained by spheroplasts was roughly 
proportional to their molecular weight. The lack of an anchoring motif resulted in a slight 
decrease in fluorescence, but nonetheless, the cell fluorescence was significantly higher 
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than background. Since an anchoring domain is not required, this approach enables more 
complex proteins consisting of multiple polypeptides to be “displayed” and engineered 
through library screening by FACS.  
The FLAG-APEx system, coupled with the optimized FACS settings, was used to 
increase the affinity of an antibody by 35-fold resulting in a KD of 100 pM following a 
single round of mutagenesis and three rounds of FACS (Chapter 4). Since clonal analysis 
following screening often represents the rate limiting step in antibody affinity maturation, 
this process was significantly expedited by rank-ordering clones isolated from the last 
round of FACS by comparing the dissociation rate constants of antibody fragments in 
crude lysates using surface Plasmon resonance (SPR). While it is well established that for 
many exogenous neutralizing antibodies increased antigen affinity correlates with 
protection (5, 101, 105, 162), the effect of antigen affinity on antibodies produced in situ 
following adenoviral gene transfer has not been examined. The variable domains from an 
affinity matured antibody (KD 100 pM) specific for the V antigen of Yersinia pestis, the 
etiological agent of the plague, and those variable domains from the antibody from which 
it was derived (KD=3.5 nM) were formatted as mouse IgG2 antibodies in separate 
adenovirus gene delivery vectors. Genetic immunization of mice with these adenoviral 
vectors resulted in similar mouse serum titers of anti-V antigen antibodies 3 days post-
immunization. Notably, the higher affinity antibody conferred increased protection 
against intranasal challenge with a 363 LD50 of Y. pestis. These results indicate that the 
affinity maturation of a neutralizing antibody delivered by genetic transfer may confer 
increased protection not only for Y. pestis challenge, but possibly for other pathogens. 
In summary, in these studies we employed the APEx system for a variety of 
purposes: (i) antibody affinity maturation (59, 60) (Chapter 4), and antibody discovery 
applications (Chapter 2), (ii) to demonstrate that the antibody format used during in vitro 
 116
selection affects which antibody variable domains can be isolated during screening 
(Chapter 2). (iii) The system was modified to increase the isolation efficiency of antigen 
specific antibodies expressed in E. coli (Chapter 3).  
 
FUTURE DIRECTIONS 
The APEx system is a versatile display technology for antibody discovery and 
engineering applications. The work presented provides an additional example of how 
APEx can be used to isolate high affinity antibody variants following a single round of 
mutagenesis and a few round of FACS (59, 60). The simultaneous detection of antigen 
binding and antibody expression levels provides additional control during screening and 
enables efficient isolation of antibodies with desirable characteristics. This approach 
should be considered the preferred methodology for future library screening by FACS. 
 Further, the incorporation of SPR and small scale antibody expression 
without purification expedites the antibody discovery process following screening by 
FACS and should be used during future affinity maturation applications. This approach is 
superior to the analysis of individual clones by enzyme-linked immunosorbent assay 
(ELISA), which is the standard approach for characterizing clones isolated from 
screening. SPR facilitates the determination of accurate dissociation rate constants 
independent of protein expression levels, which is difficult to do via ELISA and is critical 
in order to isolate the highest affinity clones. This SPR approach was used again to 
identify an antibody toward the receptor binding domain of the SAR coronavirus 
exhibiting a 200-fold affinity improvement following FACS. 
 The improved in vivo neutralization potency of the highest affinity anti-V 
antigen antibody, H8, was shown to be approximately 10-fold higher than that of the 
antibody from which it was derived. A detailed analysis of the affinity contributions of 
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each amino acid mutation should be undertaken to eliminate mutations that do not 
contribute to the enhanced affinity and may decrease specificity. 
 APEx should continue to be used as a discovery platform for antibodies 
generated from immune libraries, and the antibody format used should be dictated by the 
final application of the antibody. For example, APEx is currently being used to isolate 
antibody fragments toward the complement protein C1s from immune libraries for use in 
inflammatory diseases. Antibody fragments, which lack the Fc region, are sought after 
since antibody mediated effector function through the Fc region can lead to an increase in 
inflammation, which is opposite of the desired therapeutic effect. APEx is also being 
used to isolate full-length antibodies toward the luteinizing hormone receptor for use in 
cancer therapy since the Fc mediated effector functions are desirable in this instance.  
The ability to screen large naïve and synthetic libraries using APEx are currently 
under development as well. These approaches rely on APEx coupled with magnetic 
activated cell sorting (MACS) or phage display in order to downsize libraries containing 
more than 108 individual members, which are difficult to screen by FACS due to 
equipment limitations. Following downsizing, the power of FACS can be used for 
quantitative multi-parameter analysis to fine-tune which antibodies are selected for 
further screening and analysis. These alternative approaches will increase the application 
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